

Osteoarthritis: assessment and management (update)

[D] Evidence reviews for the benefit of weight loss for the management of osteoarthritis for people who are overweight or obese

NICE guideline <number>

Evidence reviews underpinning recommendation 1.3.5 in the NICE guideline

April 2022

Draft for Consultation

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2022. All rights reserved. Subject to [Notice of rights](#).

ISBN:

Contents

1 Benefits of weight loss for people osteoarthritis who are overweight or obese	6
1.1 Review question	6
1.1.1 Introduction.....	6
1.1.2 Summary of the protocol.....	6
1.1.3 Methods and process	8
1.1.4 Prognostic evidence	8
1.1.5 Summary of studies included in the prognostic evidence.....	9
1.1.6 Summary of the prognostic evidence.....	10
1.1.7 Economic evidence	15
1.1.8 Summary of included economic evidence.....	16
1.1.9 Economic model.....	16
1.1.11 Economic evidence statements	16
1.1.12 The committee's discussion and interpretation of the evidence	17
1.1.13 Recommendations supported by this evidence review.....	19
1.1.14 References	19
Appendices.....	25
Appendix A – Review protocols	25
Appendix B – Literature search strategies	36
B.1 Clinical search literature search strategy.....	36
B.2 Health Economics literature search strategy	38
Appendix C – Prognostic evidence study selection	42
Appendix D – Prognostic evidence	43
Appendix E – Forest plots	52
E.1 People with knee osteoarthritis who are obese – Loss of 5-10% of baseline weight compared to loss of <5% of baseline weight.....	52
E.2 People with knee osteoarthritis who are obese – Loss of >10% of baseline weight compared to loss of <5% of baseline weight.....	53
E.3 People with knee osteoarthritis who are obese – Loss of >10% of baseline weight compared to loss of 5-10% of baseline weight.....	54
E.4 People with knee osteoarthritis where their BMI classification before the study is unclear (assumed overweight [BMI 25-30] for the analysis) – Loss of 5-10% of baseline weight compared to loss of <5% of baseline weight	56
E.5 People with knee osteoarthritis where their BMI classification before the study is unclear (assumed overweight [BMI 25-30] for the analysis) – Loss of >10% of baseline weight compared to loss of <5% of baseline weight	57
E.6 People with knee osteoarthritis where their BMI classification before the study is unclear (assumed overweight [BMI 25-30] for the analysis) – Loss of >10% of baseline weight compared to loss of 5-10% of baseline weight	58
Appendix F – GRADE tables.....	59

F.1 People with knee osteoarthritis who are obese – Loss of 5-10% of baseline weight compared to loss of <5% of baseline weight.....	59
F.2 People with knee osteoarthritis who are obese – Loss of >10% of baseline weight compared to loss of <5% of baseline weight.....	60
F.3 People with knee osteoarthritis who are obese – Loss of >10% of baseline weight compared to loss of 5-10% of baseline weight.....	61
F.4 People with knee osteoarthritis where their BMI classification before the study is unclear (assumed overweight [BMI 25-30] for the analysis) – Loss of 5-10% of baseline weight compared to loss of <5% of baseline weight	62
F.5 People with knee osteoarthritis where their BMI classification before the study is unclear (assumed overweight [BMI 25-30] for the analysis) – Loss of >10% of baseline weight compared to loss of <5% of baseline weight	63
F.6 People with knee osteoarthritis where their BMI classification before the study is unclear (assumed overweight [BMI 25-30] for the analysis) – Loss of >10% of baseline weight compared to loss of 5-10% of baseline weight	64
Appendix G – Economic evidence study selection.....	65
Appendix H – Economic evidence tables	66
Appendix I – Health economic model	67
Appendix J – Excluded studies.....	68
Clinical studies	68
Health Economic studies	70

1 Benefits of weight loss for people 2 osteoarthritis who are overweight or obese

3 1.1 Review question

4 What is the benefit of weight loss for the management of osteoarthritis in overweight and
5 obese people?

6 1.1.1 Introduction

7 The benefits of weight loss in overweight and obese people are widely accepted. It is
8 believed to help reduce the risk of a variety of conditions including type 2 diabetes, heart
9 disease, stroke, some cancers and high blood pressure. While being overweight is thought to
10 exacerbate lower limb osteoarthritis through extra pressure being placed on the joints, the
11 interplay between weight and osteoarthritis is more complex than this alone, as people who
12 are overweight and obese are more likely to get osteoarthritis in non-weight bearing joints
13 such as the hand. While all the mechanisms are not completely understood, controlling
14 weight to a healthy BMI is consistently advocated internationally both for osteoarthritis and
15 general wellbeing.

16 Current practice for people with osteoarthritis is to advise them to lose weight. While most
17 overweight and obese people with osteoarthritis will agree that losing weight would help their
18 quality of life, they find it difficult to lose and sustain a weight loss. Currently, weight loss can
19 occur in through one-to-one advice or within a group setting, in some areas of the country,
20 dedicated weight loss programmes are commissioned, in others, osteoarthritis programmes
21 are commissioned which include weight loss. There is no standard approach to how people
22 with osteoarthritis should be supported to lose weight. This review aims to inform patients
23 and healthcare professionals about the amount of weight loss needed to promote
24 improvement in their osteoarthritis symptoms and joint functioning to then decide together
25 how this may best be achieved.

26

27 1.1.2 Summary of the protocol

28 **Table 1: PICO characteristics of review question**

Population	<p>Inclusion:</p> <ul style="list-style-type: none">• Adults (age ≥ 16 years) with osteoarthritis affecting any joint• People who are overweight (BMI of 25 or over) or obese (BMI of 30 or over) <p>The population will be stratified by:</p> <ul style="list-style-type: none">• Overweight or obese classification (as defined above)• Site of osteoarthritis:<ul style="list-style-type: none">○ Hip○ Knee○ Ankle○ Foot○ Toe○ Shoulder○ Elbow○ Wrist○ Hand
-------------------	--

	<ul style="list-style-type: none"> ○ Thumb ○ Finger ○ Temporomandibular joint (TMJ) ○ Multisite <p>Exclusion:</p> <ul style="list-style-type: none"> ● Children (age <16 years) ● People with conditions that may make them susceptible to osteoarthritis or often occur alongside osteoarthritis (including: crystal arthritis, inflammatory arthritis, septic arthritis, diseases of childhood that may predispose to osteoarthritis, medical conditions presenting with joint inflammation and malignancy). ● Studies with an unclear population (e.g, proportion of participants with osteoarthritis unclear) ● Spinal osteoarthritis
Prognostic variables under consideration	<p>Weight loss by any means resulting in:</p> <ul style="list-style-type: none"> ● Weight loss <5% ● 5-10% ● >10%
Confounding factors	<p>Confounding factors:</p> <ul style="list-style-type: none"> ● Baseline BMI (or weight in the absence of BMI) ● Baseline symptoms such as pain and/or function ● Intervention (if sample selected/were randomised to various interventions) ● Age
Outcomes	<p>Stratify by \leq/$>$3 months (longest time-point in each):</p> <p>Critical outcomes:</p> <ul style="list-style-type: none"> ● Health-related quality of life [validated patient-reported outcomes, continuous data prioritised] ● Physical function [validated patient-reported outcomes, continuous data prioritised] ● Pain [validated patient-reported outcomes, continuous data prioritised] <p>Important outcomes:</p> <ul style="list-style-type: none"> ● Psychological distress [validated patient-reported outcomes, continuous data prioritised] ● Osteoarthritis flares [validated patient-reported outcomes, continuous data prioritised]
Study design	<p>Non-randomised evidence, including:</p> <ol style="list-style-type: none"> 1. Secondary analyses of RCTs (stratified results by weight loss) 2. Prospective and retrospective cohort studies 3. Case control studies (if no other evidence identified) <p>Studies will only be included if all of the key confounders have been accounted for in a multivariate analysis. In the absence of multivariate analysis, studies that account for key confounders with univariate analysis or matched groups will be considered.</p>

1 For full details see the review protocol in Appendix A.

1 **1.1.3 Methods and process**

2 This evidence review was developed using the methods and process described in
3 [Developing NICE guidelines: the manual](#). Methods specific to this review question are
4 described in the review protocol in Appendix A and the methods document.

5 were recorded according to [NICE's conflicts of interest policy](#).

6 **1.1.4 Prognostic evidence**

7 **1.1.4.1 Included studies**

8 Two prospective cohort studies were included in the review^{3, 55}; these are summarised in
9 below. Evidence from these studies is summarised in the clinical evidence summary below
10 (Table 3). These studies included people who were either obese³ or where the proportion of
11 people who were obese or overweight is unclear⁵⁵. All studies included people with knee
12 osteoarthritis. No relevant clinical studies investigated the effects on people with
13 osteoarthritis of different joint sites. One study accounted for all confounders within a
14 regression analysis³, while the other accounted for some of these confounders in a
15 regression analysis while other confounders were matched at baseline⁵⁵.

16 See also the study selection flow chart in Appendix A, study evidence tables in Appendix D,
17 forest plots in Appendix E and GRADE tables in Appendix F.

18 **1.1.4.2 Excluded studies**

19 See the excluded studies list in Appendix J.

1 **1.1.5 Summary of studies included in the prognostic evidence**2 **Table 2: Summary of studies included in the evidence review**

Study	Population	Analysis	Prognostic variable	Confounders	Outcomes	Limitations
Atukorala 2016 ³	Knee osteoarthritis People with knee osteoarthritis of whom the majority were obese (1130/81.7%) n=1383	Repeated-measures of analysis of variance, controlling for sex, age, body mass index and KOOS	Weight loss: Loss of ≤5% of baseline weight Loss of 5-10% of baseline weight Loss of ≥10% of baseline weight	Age Body mass index Baseline weight	Quality of life at >3 months Pain at >3 months Physical function at >3 months	Very high risk of bias (bias due to problems with study participation and study attrition)
Riddle 2013 ⁵⁵	Knee osteoarthritis People with knee osteoarthritis of whom it is unclear what their baseline BMI category was. For the analysis this group is treated as if overweight. n=1410	Regression analysis adjusting for baseline symptoms, sex, depression and number of comorbidities	Weight loss: Loss of ≤5% of baseline weight Loss of 5-10% of baseline weight Loss of ≥10% of baseline weight	Regression analysis: Baseline symptoms Baseline values available and stated to be similar at baseline between different weight categories: Age Baseline weight	Pain at >3 months Physical function at >3 months	Very high risk of bias (bias due to problems with study participation and study confounding)

3 See Appendix D for full evidence tables.

1.1.6 Summary of the prognostic evidence

Table 3: Clinical evidence summary: loss of 5-10% of baseline weight compared to loss of <5% of baseline weight for people with knee osteoarthritis who are obese (BMI ≥30)

Risk factor and outcome (population)	Number of studies	Effect (95% CI)	Imprecision	GRADE Quality	MID
Loss of 5-10% of baseline weight compared to loss of <5% of baseline weight Quality of life (KOOS, 0-100, high is good, change score) at >3 months (follow up: 18 weeks) (people with knee osteoarthritis who are obese) ^a	1	MD 3.40 (0.66 to 6.14) SMD 0.15 SD (0.01 to 0.29)	Not serious	LOW _b	0.5 SD (SMD)
Loss of 5-10% of baseline weight compared to loss of <5% of baseline weight Pain (KOOS, 0-100, high is good, change score) at >3 months (follow up: 18 weeks) (people with knee osteoarthritis who are obese) ^a	1	MD 3.70 (1.51 to 5.89) SMD 0.23 SD (0.09 to 0.37)	Not serious	LOW _b	0.5 SD (SMD)
Loss of 5-10% of baseline weight compared to loss of <5% of baseline weight Physical function (KOOS, 0-100, high is good, change score) at >3 months (follow up: 18 weeks) (people with knee osteoarthritis who are obese) ^a	1	MD 4.20 (2.16 to 6.24) SMD 0.27 SD (0.13 to 0.41)	Not serious	LOW _b	0.5 SD (SMD)

(a) Methods: multivariable analysis, including key covariates used in analysis to assess if weight change is an independent risk factor. Key covariates included: sex, age, BMI, KOOS scores.

(b) Downgraded for risk of bias (see evidence table for additional information).

Table 4: Clinical evidence summary: >10% of baseline weight compared to loss of <5% of baseline weight for people with knee osteoarthritis who are obese (BMI ≥30)

Risk factor and outcome (population)	Number of studies	Effect (95% CI)	Imprecision	GRADE Quality	MID
Loss of >10% of baseline weight compared to loss of <5% of baseline weight Quality of life (KOOS, 0-100, high is good, change score) at >3 months (follow up: 18 weeks) (people with knee osteoarthritis who are obese) ^a	1	MD 7.50 (4.89 to 10.11) SMD 0.42 SD (0.27 to 0.57)	Not serious	LOW _b	0.5 SD (SMD)

Risk factor and outcome (population)	Number of studies	Effect (95% CI)	Imprecision	GRADE Quality	MID
Loss of >10% of baseline weight compared to loss of <5% of baseline weight Pain (KOOS, 0-100, high is good, change score) at >3 months (follow up: 18 weeks) (people with knee osteoarthritis who are obese) ^a	1	MD 7.80 (5.44 to 10.16) SMD 0.42 SD (0.27 to 0.57)	Not serious	LOW _b	0.5 SD (SMD)
Loss of >10% of baseline weight compared to loss of <5% of baseline weight Physical function (KOOS, 0-100, high is good, change score) at >3 months (follow up: 18 weeks) (people with knee osteoarthritis who are obese) ^a	1	MD 8.80 (6.56 to 11.04) SMD 0.57 SD (0.42 to 0.72)	Not serious	LOW _b	0.5 SD (SMD)

(a) Methods: multivariable analysis, including key covariates used in analysis to assess if weight change is an independent risk factor. Key covariates included: sex, age, BMI, KOOS scores.

(b) Downgraded for risk of bias (see evidence table for additional information).

Table 5: Clinical evidence summary: >10% of baseline weight compared to loss of 5-10% of baseline weight for people with knee osteoarthritis who are obese (BMI ≥30)

Risk factor and outcome (population)	Number of studies	Effect (95% CI)	Imprecision	GRADE Quality	MID
Loss of >10% of baseline weight compared to loss of 5-10% of baseline weight Quality of life (KOOS, 0-100, high is good, change score) at >3 months (follow up: 18 weeks) (people with knee osteoarthritis who are obese) ^a	1	MD 4.10 (1.53 to 6.67) SMD 0.18 SD (0.06 to 0.30)	Not serious	LOW	0.5 SD (SMD)
Loss of >10% of baseline weight compared to loss of 5-10% of baseline weight Pain (KOOS, 0-100, high is good, change score) at >3 months (follow up: 18 weeks) (people with knee osteoarthritis who are obese) ^a	1	MD 4.10 (2.13 to 6.07) SMD 0.25 SD (0.13 to 0.38)	Not serious	LOW	0.5 SD (SMD)
Loss of >10% of baseline weight compared to loss of 5-10% of baseline weight Physical function (KOOS, 0-100, high is good, change score) at >3 months (follow up: 18 weeks) (people with knee osteoarthritis who are obese) ^a	1	MD 4.60 (2.62 to 6.58) SMD 0.28 SD (0.16 to 0.41)	Not serious	LOW	0.5 SD (SMD)

(a) Methods: multivariable analysis, including key covariates used in analysis to assess if weight change is an independent risk factor. Key covariates included: sex, age, BMI, KOOS scores.

(b) Downgraded for risk of bias (see evidence table for additional information).

Table 6: Clinical evidence summary: loss of 5-10% of baseline weight compared to loss of <5% of baseline weight for people with knee osteoarthritis where their BMI classification before the study is unclear (assumed overweight [BMI 25-30] for the analysis)

Risk factor and outcome (population)	Number of studies	Effect (95% CI)	Imprecision	GRADE Quality	MID
Loss of 5-10% of baseline weight compared to loss of <5% of baseline weight Pain (WOMAC, 0-20, high is poor, change score) at >3 months (follow up: 30 months) (people with knee osteoarthritis where their baseline BMI category is unclear) ^a	1	MD 0.10 (-0.60 to 0.80) SMD 0.03 SD (-0.14 to 0.19)	Serious _b	VERY LOW _c	0.5 SD (SMD)
Loss of 5-10% of baseline weight compared to loss of <5% of baseline weight Physical function (WOMAC, 0-68, high is poor, change score) at >3 months (follow up: 30 months) (people with knee osteoarthritis where their baseline BMI category is unclear) ^a	1	MD -0.56 (-2.60 to 1.48) SMD -0.05 SD (-0.21 to 0.12)	Serious _b	VERY LOW _c	0.5 SD (SMD)

(a) Methods: multivariable analysis, including key covariates used in analysis to assess if weight change is an independent risk factor. Key covariates included: baseline symptoms, sex, depression, number of comorbidities. Factors with evidence to indicate they were matched between groups at baseline: baseline weight, age.

(b) 95% CI around the mean difference crosses null line.

(c) Downgraded for risk of bias (see evidence table for additional information).

Table 7: Clinical evidence summary: loss of >10% of baseline weight compared to loss of <5% of baseline weight for people with knee osteoarthritis where their BMI classification before the study is unclear (assumed overweight [BMI 25-30] for the analysis)

Risk factor and outcome (population)	Number of studies	Effect (95% CI)	Imprecision	GRADE Quality	MID
Loss of >10% of baseline weight compared to loss of <5% of baseline weight Pain (WOMAC, 0-20, high is poor, change score) at >3 months (follow up: 30 months)	1	MD -0.96 (-1.99 to 0.07) SMD -0.24 SD (-0.47 to -0.02)	Serious _b	VERY LOW _c	0.5 SD (SMD)

Risk factor and outcome (population)	Number of studies	Effect (95% CI)	Imprecision	GRADE Quality	MID
(people with knee osteoarthritis where their baseline BMI category is unclear) ^a					
Loss of >10% of baseline weight compared to loss of <5% of baseline weight Physical function (WOMAC, 0-68, high is poor, change score) at >3 months (follow up: 30 months) (people with knee osteoarthritis where their baseline BMI category is unclear) ^a	1	MD -4.72 (-7.68 to -1.76) SMD -0.40 SD (-0.62 to -0.17)	Not serious	LOW ^c	0.5 SD (SMD)

1 (a) Methods: multivariable analysis, including key covariates used in analysis to assess if weight change is an independent risk factor. Key covariates included: baseline symptoms, sex, depression,
2 number of comorbidities. Factors with evidence to indicate they were matched between groups at baseline: baseline weight, age.

3 (b) 95% CI around the mean difference crosses null line.

4 (c) Downgraded for risk of bias (see evidence table for additional information).

5

6 **Table 8: Clinical evidence summary: loss of >10% of baseline weight compared to loss of 5-10% of baseline weight for people with knee**
7 **osteoarthritis where their BMI classification before the study is unclear (assumed overweight [BMI 25-30] for the analysis)**

Risk factor and outcome (population)	Number of studies	Effect (95% CI)	Imprecision	GRADE Quality	MID
Loss of >10% of baseline weight compared to loss of 5-10% of baseline weight Pain (WOMAC, 0-20, high is poor, change score) at >3 months (follow up: 30 months) (people with knee osteoarthritis where their baseline BMI category is unclear) ^a	1	MD -1.06 (-2.25 to 0.13) SMD -0.24 SD (-0.50 to 0.03)	Serious ^b	VERY LOW ^c	0.5 SD (SMD)
Loss of >10% of baseline weight compared to loss of 5-10% of baseline weight Physical function (WOMAC, 0-68, high is poor, change score) at >3 months (follow up: 30 months) (people with knee osteoarthritis where their baseline BMI category is unclear) ^a	1	MD -4.16 (-7.59 to -0.73) SMD -0.32 SD (-0.59 to -0.06)	Not serious	LOW ^c	0.5 SD (SMD)

- 1 (a) *Methods: multivariable analysis, including key covariates used in analysis to assess if weight change is an independent risk factor. Key covariates included: baseline symptoms, sex, depression,*
- 2 *number of comorbidities. Factors with evidence to indicate they were matched between groups at baseline: baseline weight, age.*
- 3 (b) *95% CI around the mean difference crosses null line.*
- 4 (c) *Downgraded for risk of bias (see evidence table for additional information).*

5 See Appendix F for full GRADE tables.

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

1 **1.1.7 Economic evidence**

2 **1.1.7.1 Included studies**

3 No health economic studies were included.

4 **1.1.7.2 Excluded studies**

5 No relevant health economic studies were excluded due to assessment of limited
6 applicability or methodological limitations.

7 See also the health economic study selection flow chart in Appendix G.

8

1 **1.1.8 Summary of included economic evidence**

2 There was no economic evidence found

3 **1.1.9 Economic model**

4 This area was not prioritised for new cost-effectiveness analysis.

5 **1.1.11 Economic evidence statements**

6 • No relevant economic evaluations were identified.

7

1 **1.1.12 The committee's discussion and interpretation of the evidence**

2 **1.1.12.1. The outcomes that matter most**

3 The critical outcomes were quality of life, pain and physical function. These were considered
4 critical due to their relevance importance to people with osteoarthritis. The Osteoarthritis
5 Research Society International (OARSI) consider that pain and physical function were the
6 most important outcomes for evaluating interventions. Quality of life gives a broader
7 perspective on the person's wellbeing, allowing for examination of the biopsychosocial
8 impact of interventions. Psychological distress and osteoarthritis flares were included as
9 important outcomes.

10 The committee considered osteoarthritis flares to be important in the lived experience and
11 management of osteoarthritis. However, these were also considered difficult to measure with
12 no clear consensus on their definition. The Flares in OA OMERACT working group have
13 proposed an initial definition and domains of OA flares through a consensus exercise; "it is a
14 transient state, different from the usual state of the condition, with a duration of a few days,
15 characterized by onset, worsening of pain, swelling, stiffness, impact on sleep, activity,
16 functioning, and psychological aspects that can resolve spontaneously or lead to a need to
17 adjust therapy.". However, this has been considered to have limitations and has not been
18 widely adopted. Therefore, the committee included the outcome accepting any reasonable
19 definition provided by any studies discussing the event.

20 Mortality was included as treatment adverse events rather than as a discreet outcome and
21 categorised as an important outcome. Osteoarthritis as a disease process is not considered
22 to cause mortality by itself and mortality is an uncommon outcome from osteoarthritis
23 interventions.

24 There was no evidence available for osteoarthritis flares and psychological distress. The
25 committee acknowledged these as important outcomes rather than critical and agreed that
26 they could make recommendations even though there was limited information for this
27 outcome.

28 **1.1.12.2 The quality of the evidence**

29 Two studies were included in this review. The first (Atukorala 2016³) included people with
30 knee osteoarthritis who were obese and investigated the effect of losing $\leq 5\%$, 5-10% and
31 $\geq 10\%$ of their baseline weight after participating in a weight loss management program. The
32 second (Riddle 2013⁵⁵) included people with knee osteoarthritis where it was unclear
33 whether they were overweight or obese before entering the study. It also investigated the
34 effect of losing $\leq 5\%$, 5-10% and $\geq 10\%$ of their baseline weight after participating in two
35 different weight loss management programs. These studies were not pooled for analysis as
36 the populations were not comparable (one including only people who were obese, one
37 comparing people who were overweight or obese) and different methods used to analyse the
38 effect of confounders.

39 All outcomes were noted to be of very high risk of bias. The reasons for this included bias in
40 study participation (as the inclusion and exclusion criteria are unclear), study attrition (as the
41 proportion of baseline sample available for analysis was inadequate and there was
42 insufficient information on why participants were lost to follow up) and study confounding (as
43 not all confounding factors established in the protocol were accounted for in a multivariate
44 analysis). No indirectness was noted in any outcomes. Imprecision was noted in four
45 outcomes, including participants where their BMI classification before entering the study is
46 unclear.

1 **1.1.12.3 Clinical effects of weight loss**

2 For people with knee osteoarthritis who were obese, the outcomes reported were quality of
3 life, pain and physical function. For people with knee osteoarthritis where their BMI
4 classification before the study was unclear, the outcomes reported were pain and physical
5 function. All outcomes were reported at >3 months (18 weeks and 30 months respectively).
6 In people who were obese, the results showed that people who have a >10% weight loss
7 have a clinically important improvement in physical function at >3 months when compared to
8 people with a loss of <5% of their baseline weight. Other outcomes did not show evidence of
9 a clinically important effect using a standardised mean difference value of 0.5. However, in
10 all outcomes participants achieved a beneficial effect to quality of life, pain and physical
11 function at >3 months to lesser degrees (with standardised mean difference values between
12 0.15-0.27 for quality of life, pain and physical function for people losing 5-10% of their
13 baseline weight compared to people with a <5% loss, and 0.42 in quality of life and pain for
14 people losing >10% of their baseline weight compared to people with a <5% loss).

15 For people with knee osteoarthritis and an unclear BMI classification before the study no
16 outcomes showed a clinically important change. The effects at >3 months with a loss of 5-
17 10% of baseline weight had small effect sizes (for standardised mean differences where high
18 is poor, pain = 0.03, physical function = -0.05) while the effects with a loss of >10% of
19 baseline weight there were larger effect sizes indicating a possible benefit (pain = -0.24,
20 physical function = -0.40). There was no evidence identified for the outcomes of osteoarthritis
21 flares or psychological distress.

22 The committee acknowledged that there was a trend that increased weight loss led to better
23 outcomes reflecting that the evidence indicated a dose-response gradient (with >10% weight
24 loss group appearing to have a much more significant change than the <5% weight loss
25 group). They acknowledged that the studies included achieved the higher amounts of weight
26 loss through a formal weight loss programme, and so considered that support should be
27 provided to people to help them to lose weight. However, the committee considered that the
28 support required for people with osteoarthritis would be similar to from the support required
29 for people with other conditions and so recommended to consider other relevant NICE
30 guidance for this information (including: [Weight management: lifestyle services for](#)
31 [overweight or obese adults](#) (PH53) and [Obesity: identification, assessment and management](#)
32 (CG189)). Due to the observed benefits of weight loss the committee made a
33 recommendation to advise people about weight loss and to support them to make meaningful
34 weight loss goals. The committee noted that benefits were seen with all amounts of weight
35 loss, with the most benefits being seen when $\geq 10\%$ of their body weight was lost. To this
36 end, they recommended that people lose as much weight as they can but wanted to
37 encourage that losing any weight was likely to provide benefits for people with osteoarthritis
38 who are overweight or obese.

39 Furthermore, the committee agreed that good practice should be used in supporting people
40 to achieve this weight loss. This should include helping people to choose an achievable
41 weight goal. The committee agreed that while there was limited evidence available, the
42 evidence was sufficient to make a recommendation and therefore, no additional research
43 was required in this area.

44 **1.1.12.4 Cost effectiveness and resource use**

45 No economic evaluations were identified for this question.

46 The clinical review showed a trend between greater weight loss and improved reported
47 health outcomes. Conclusions could not be made regarding the cost effectiveness of
48 structured weight loss programmes in osteoarthritis, however the committee agreed that
49 some form of patient support should be indicated based on the clinical evidence, and
50 motivational interviewing and health coaching techniques were suggested.

1 The committee acknowledged that the recommendation would require the time of a
2 healthcare professional but did not think it would lead to a substantial resource impact since
3 this recommendation is intended to build upon likely unstructured conversations that are
4 already occurring.

5 **1.1.12.5 Other factors the committee took into account**

6 Studies did not report if weight loss was maintained over this time period. The committee
7 acknowledged the challenges of maintaining weight loss over a long period of time and that
8 in order to maintain the benefits, maintained weight loss would be useful. They wanted to
9 reinforce that good practice for supporting people with weight management should be used
10 (such as those in other relevant NICE guidance) to help people maintain any weight loss that
11 they achieve.

12 Overweight and obese people with osteoarthritis are often told to lose weight before they will
13 be considered for joint replacement. However, losing weight may require exercise (for more
14 information about exercise for osteoarthritis see evidence review C) and people report having
15 difficulty exercising when they have joint pain, and it is uncertain whether losing weight
16 before a joint replacement is required. The effect of people being in different BMI categories
17 before joint replacement surgery is considered in evidence review 'Outcomes of joint
18 replacement surgery dependent on body mass index', which investigates elements of this.

19 **1.1.13 Recommendations supported by this evidence review**

20 This evidence review supports recommendation 1.3.5. Other evidence supporting this
21 recommendation can be found in evidence review D.

22 **1.1.14 References**

- 23 1. Aaboe J, Bliddal H, Messier SP, Alkjaer T, Henriksen M. Effects of an intensive
24 weight loss program on knee joint loading in obese adults with knee osteoarthritis.
25 *Osteoarthritis and Cartilage*. 2011; 19(7):822-828
- 26 2. Anandacoomarasamy A, Leibman S, Smith G, Caterson I, Giuffre B, Fransen M et al.
27 Weight loss in obese people has structure-modifying effects on medial but not on
28 lateral knee articular cartilage. *Annals of the Rheumatic Diseases*. 2012; 71(1):26-32
- 29 3. Atukorala I, Makovey J, Lawler L, Messier SP, Bennell K, Hunter DJ. Is there a dose-
30 response relationship between weight loss and symptom improvement in persons
31 with knee osteoarthritis? *Arthritis Care and Research*. 2016; 68(8):1106-1114
- 32 4. Bliddal H, Christensen P, Riecke BF, Aaboe J, Frederiksen R, Bartels E et al.
33 Osteoarthritis - a role for weight management in rheumatology practice: an update.
34 *Clinical Obesity*. 2011; 1(1):50-52
- 35 5. Bliddal H, Leeds AR, Christensen R. Osteoarthritis, obesity and weight loss:
36 evidence, hypotheses and horizons - a scoping review. *Obesity Reviews*. 2014;
37 15(7):578-586
- 38 6. Brennan SL, Cicuttini FM, Pasco JA, Henry MJ, Wang Y, Kotowicz MA et al. Does an
39 increase in body mass index over 10 years affect knee structure in a population-
40 based cohort study of adult women? *Arthritis Research & Therapy*. 2010; 12(4):R139
- 41 7. Chu IJH, Lim AYT, Ng CLW. Effects of meaningful weight loss beyond symptomatic
42 relief in adults with knee osteoarthritis and obesity: a systematic review and meta-
43 analysis. *Obesity Reviews*. 2018; 19(11):1597-1607

- 1 8. Cuzdan Coskun N, Ay S, Evcik FD, Oztuna D. Adiponectin: is it a biomarker for
2 assessing the disease severity in knee osteoarthritis patients? *International Journal of*
3 *Rheumatic Diseases*. 2017; 20(12):1942-1949
- 4 9. Daugaard CL, Henriksen M, Riis RGC, Bandak E, Nybing JD, Hangaard S et al. The
5 impact of a significant weight loss on inflammation assessed on DCE-MRI and static
6 MRI in knee osteoarthritis: a prospective cohort study. *Osteoarthritis and Cartilage*.
7 2020; 28(6):766-773
- 8 10. de Luis DA, Izaola O, Garcia Alonso M, Aller R, Cabezas G, de la Fuente B. Effect of
9 a hypocaloric diet with a commercial formula in weight loss and quality of life in obese
10 patients with chronic osteoarthritis. *Nutricion Hospitalaria*. 2012; 27(5):1648-1654
- 11 11. DeClercq V, Cui Y, Forbes C, Grandy SA, Keats M, Parker L et al. Adiposity
12 measures and plasma adipokines in females with rheumatoid and osteoarthritis.
13 *Mediators of Inflammation*. 2017; 2017:4302412
- 14 12. Edwards C, Rogers A, Lynch S, Pylawka T, Silvis M, Chinchilli V et al. The effects of
15 bariatric surgery weight loss on knee pain in patients with osteoarthritis of the knee.
16 *Arthritis*. 2012; 2012:504189
- 17 13. Felson D, Rabasa G, Jafarzadeh SR, Nevitt M, Lewis CE, Segal N et al. Factors
18 associated with pain resolution in those with knee pain: the MOST study.
19 *Osteoarthritis and cartilage*. 2021; 29(12):1666-1672
- 20 14. Felson DT. Weight and osteoarthritis. *American Journal of Clinical Nutrition*. 1996;
21 63(Suppl 3):430S-432S
- 22 15. Felson DT, Goggins J, Niu J, Zhang Y, Hunter DJ. The effect of body weight on
23 progression of knee osteoarthritis is dependent on alignment. *Arthritis and*
24 *Rheumatism*. 2004; 50(12):3904-3909
- 25 16. Fonseca Mora MC, Milla Matute CA, Ferri F, Lo Menzo E, Szmostein S, Rosenthal
26 RJ. Reduction of invasive interventions in severely obese with osteoarthritis after
27 bariatric surgery. *Surgical Endoscopy*. 2020; 34(8):3606-3613
- 28 17. Gersing AS, Schwaiger BJ, Nevitt MC, Zarnowski J, Joseph GB, Feuerriegel G et al.
29 Weight loss regimen in obese and overweight individuals is associated with reduced
30 cartilage degeneration: 96-month data from the Osteoarthritis Initiative. *Osteoarthritis*
31 *and Cartilage*. 2019; 27(6):863-870
- 32 18. Gersing AS, Schwaiger BJ, Nevitt MC, Zarnowski J, Joseph GB, Feuerriegel G et al.
33 Weight loss regimen in obese and overweight individuals is associated with reduced
34 cartilage degeneration: 96-month data from the Osteoarthritis Initiative. *Osteoarthritis*
35 *and Cartilage*. 2019; 27(6):863-870
- 36 19. Gersing AS, Solka M, Joseph GB, Schwaiger BJ, Heilmeyer U, Feuerriegel G et al.
37 Progression of cartilage degeneration and clinical symptoms in obese and overweight
38 individuals is dependent on the amount of weight loss: 48-month data from the
39 Osteoarthritis Initiative. *Osteoarthritis and Cartilage*. 2016; 24(7):1126-1134
- 40 20. Gorsky RD, Pamuk E, Williamson DF, Shaffer PA, Koplan JP. The 25-year health
41 care costs of women who remain overweight after 40 years of age. *American Journal*
42 *of Preventive Medicine*. 1996; 12(5):388-394
- 43 21. Gudbergson H, Boesen M, Christensen R, Bartels EM, Henriksen M, Danneskiold-
44 Samsoe B et al. Changes in bone marrow lesions in response to weight-loss in obese
45 knee osteoarthritis patients: a prospective cohort study. *BMC Musculoskeletal*
46 *Disorders*. 2013; 14:106

- 1 22. Guimaraes JB, Nevitt MC, McCulloch CE, Schwaiger BJ, Gersing AS, Facchetti L et
2 al. Association of weight change with progression of meniscal intrasubstance
3 degeneration over 48 months: Data from the Osteoarthritis Initiative. *European*
4 *Radiology*. 2018; 28(3):953-962
- 5 23. Hacken B, Rogers A, Chinchilli V, Silvis M, Mosher T, Black K. Improvement in knee
6 osteoarthritis pain and function following bariatric surgery: 5-year follow-up. *Surgery*
7 *for Obesity and Related Diseases*. 2019; 15(6):979-984
- 8 24. Hall M, Castelein B, Wittoek R, Calders P, Van Ginckel A. Diet-induced weight loss
9 alone or combined with exercise in overweight or obese people with knee
10 osteoarthritis: A systematic review and meta-analysis. *Seminars in Arthritis and*
11 *Rheumatism*. 2019; 48(5):765-777
- 12 25. Hamdi A, Albaghdadi AT, Ghalimah B, Alnowiser A, Ahmad A, Altaf A. Bariatric
13 surgery improves knee function and not knee pain in the early postoperative period.
14 *Journal of Orthopaedic Surgery*. 2018; 13(1):82
- 15 26. Hawker GA, Croxford R, Bierman AS, Harvey PJ, Ravi B, Stanaitis I et al. All-cause
16 mortality and serious cardiovascular events in people with hip and knee osteoarthritis:
17 A population based cohort study. *PloS One*. 2014; 9 (3):e91286
- 18 27. Inacio MC, Paxton EW, Fisher D, Li RA, Barber TC, Singh JA. Bariatric surgery prior
19 to total joint arthroplasty may not provide dramatic improvements in post-arthroplasty
20 surgical outcomes. *Journal of Arthroplasty*. 2014; 29(7):1359-1364
- 21 28. Jafarzadeh SR, Clancy M, Li JS, Apovian CM, Guermazi A, Eckstein F et al. Changes
22 in the structural features of osteoarthritis in a year of weight loss. *Osteoarthritis and*
23 *Cartilage*. 2018; 26(6):775-782
- 24 29. Jin X, Gibson AA, Gale J, Schneuer F, Ding D, March L et al. Does weight loss
25 reduce the incidence of total knee and hip replacement for osteoarthritis?-A
26 prospective cohort study among middle-aged and older adults with overweight or
27 obesity. *International Journal of Obesity*. 2021; 45(8):1696-1704
- 28 30. Kalichman L, Kobylansky E. Age, body composition, and reproductive indices as
29 predictors of radiographic hand osteoarthritis in Chuvashian women. *Scandinavian*
30 *Journal of Rheumatology*. 2007; 36(1):53-57
- 31 31. Kannus P, Jarvinen M. Age, overweight, sex, and knee instability: their relationship to
32 the post-traumatic osteoarthrosis of the knee joint. *Injury*. 1988; 19(2):105-108
- 33 32. Kim M. Weight control in postmenopausal korean patients with osteo-arthritis. *Iranian*
34 *Journal of Public Health*. 2020; 49(12):2400-2408
- 35 33. King LK, Henneicke H, Seibel MJ, March L, Anandacoomarasmy A. Association of
36 adipokines and joint biomarkers with cartilage-modifying effects of weight loss in
37 obese subjects. *Osteoarthritis and Cartilage*. 2015; 23(3):397-404
- 38 34. King WC, Chen JY, Belle SH, Courcoulas AP, Dakin GF, Elder KA et al. Change in
39 pain and physical function following bariatric surgery for severe obesity. *JAMA*. 2016;
40 315(13):1362-1371
- 41 35. Larsen VH, Sorensen KH. Weight reduction before hip replacement. *Acta*
42 *Orthopaedica Scandinavica*. 1980; 51(5):841-844
- 43 36. Li JS, Tsai TY, Clancy MM, Li G, Lewis CL, Felson DT. Weight loss changed gait
44 kinematics in individuals with obesity and knee pain. *Gait and Posture*. 2019; 68:461-
45 465

- 1 37. Magnusson K, Slatkowsky-Christensen B, van der Heijde D, Kvien TK, Hagen KB,
2 Haugen IK. Body mass index and progressive hand osteoarthritis: data from the Oslo
3 hand osteoarthritis cohort. *Scandinavian Journal of Rheumatology*. 2015; 44(4):331-
4 336
- 5 38. Martin K, Fontaine KR, Nicklas BJ, Dennis KE, Goldberg AP, Hochberg MC. Weight
6 loss and exercise walking reduce pain and improve physical functioning in overweight
7 postmenopausal women with knee osteoarthritis. *JCR: Journal of Clinical*
8 *Rheumatology*. 2001; 7(4):219-223
- 9 39. Messier SP. Physical activity and weight loss interventions in older adults with knee
10 osteoarthritis. *North Carolina Medical Journal*. 2007; 68(6):436-438
- 11 40. Messier SP, Newman JJ, Scarlett MJ, Mihalko SL, Miller GD, Nicklas BJ et al.
12 Changes in body weight and knee pain in adults with knee osteoarthritis 3.5 years
13 after completing diet and exercise interventions. *Arthritis Care and Research*. 2021;
14 Epub
- 15 41. Messier SP, Newman JJ, Scarlett MJ, Mihalko SL, Miller GD, Nicklas BJ et al.
16 Changes in body weight and knee pain in adults with knee osteoarthritis 3.5 years
17 after completing diet and exercise interventions. *Arthritis care & research*. 2021; 09
- 18 42. Moss AS, Murphy LB, Helmick CG, Schwartz TA, Barbour KE, Renner JB et al.
19 Annual incidence rates of hip symptoms and three hip OA outcomes from a U.S.
20 population-based cohort study: the Johnston County Osteoarthritis Project.
21 *Osteoarthritis and Cartilage*. 2016; 24(9):1518-1527
- 22 43. Munugoda IP, Beavers DP, Wirth W, Aitken DA, Loeser RF, Miller GD et al. The
23 effect of weight loss on the progression of meniscal extrusion and size in knee
24 osteoarthritis: a post-hoc analysis of the Intensive Diet and Exercise for Arthritis
25 (IDEA) trial. *Osteoarthritis and Cartilage*. 2020; 28(4):410-417
- 26 44. Murphy LB, Moss S, Do BT, Helmick CG, Schwartz TA, Barbour KE et al. Annual
27 incidence of knee symptoms and four knee osteoarthritis outcomes in the Johnston
28 county osteoarthritis project. *Arthritis Care and Research*. 2016; 68(1):55-65
- 29 45. National Institute for Health and Care Excellence. Developing NICE guidelines: the
30 manual [updated October 2020]. London. National Institute for Health and Care
31 Excellence, 2014. Available from: <https://www.nice.org.uk/process/pmg20>
- 32 46. Nicholls AS, Kiran A, Javaid MK, Hart DJ, Spector TD, Carr AJ et al. Change in body
33 mass index during middle age affects risk of total knee arthroplasty due to
34 osteoarthritis: a 19-year prospective study of 1003 women. *Knee*. 2012; 19(4):316-
35 319
- 36 47. Nuesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Juni P. All cause and disease
37 specific mortality in patients with knee or hip osteoarthritis: population based cohort
38 study. *BMJ*. 2011; 342:d1165
- 39 48. Paans N, van den Akker-Scheek I, Dilling RG, Bos M, van der Meer K, Bulstra SK et al.
40 Effect of exercise and weight loss in people who have hip osteoarthritis and are
41 overweight or obese: a prospective cohort study. *Physical Therapy*. 2013; 93(2):137-
42 146
- 43 49. Pellegrini CA, Song J, Chang RW, Semanik PA, Lee J, Ehrlich-Jones L et al. Change
44 in physical activity and sedentary time associated with 2-year weight loss in obese
45 adults with osteoarthritis. *Journal of Physical Activity & Health*. 2016; 13(5):461-466

- 1 50. Pi-Sunyer FX. A review of long-term studies evaluating the efficacy of weight loss in
2 ameliorating disorders associated with obesity. *Clinical Therapeutics*. 1996;
3 18(6):1006-1035; discussion 1005
- 4 51. Pogacnik Murillo AL, Eckstein F, Wirth W, Beavers D, Loeser RF, Nicklas BJ et al.
5 Impact of diet and/or exercise intervention on infrapatellar fat pad morphology:
6 Secondary analysis from the intensive diet and exercise for arthritis (IDEA) trial. *Cells*
7 *Tissues Organs*. 2017; 203(4):258-266
- 8 52. Ravikumar H, Mohanraj KG, Don KR. Association between increasing age, obesity
9 and heredity with osteoarthritis of knee joint among middle aged and old aged
10 population. *International Journal of Research in Pharmaceutical Sciences*. 2020;
11 11(Special Issue 3):765-772
- 12 53. Reyes C, Leyland KM, Peat G, Cooper C, Arden NK, Prieto-Alhambra D. Association
13 between overweight and obesity and risk of clinically diagnosed knee, hip, and hand
14 osteoarthritis: A population-based cohort study. *Arthritis & Rheumatology*. 2016;
15 68(8):1869-1875
- 16 54. Richette P, Poitou C, Garnero P, Vicaut E, Bouillot JL, Lacorte JM et al. Benefits of
17 massive weight loss on symptoms, systemic inflammation and cartilage turnover in
18 obese patients with knee osteoarthritis. *Annals of the Rheumatic Diseases*. 2011;
19 70(1):139-144
- 20 55. Riddle DL, Stratford PW. Body weight changes and corresponding changes in pain
21 and function in persons with symptomatic knee osteoarthritis: a cohort study. *Arthritis*
22 *Care and Research*. 2013; 65(1):15-22
- 23 56. Rishi L, Bhandari M, Kumar R. Can bariatric surgery delay the need for knee
24 replacement in morbidly obese osteoarthritis patients. *Journal of Minimal Access*
25 *Surgery*. 2018; 14(1):13-17
- 26 57. Rosemann T, Grol R, Herman K, Wensing M, Szecsenyi J. Association between
27 obesity, quality of life, physical activity and health service utilization in primary care
28 patients with osteoarthritis. *International Journal of Behavioral Nutrition & Physical*
29 *Activity*. 2008; 5:4
- 30 58. Sarumathy S, Balasudhakar C. Assessment of health-related quality of life and
31 predictors of risk factors in patients with knee osteoarthritis. *International Journal of*
32 *PharmTech Research*. 2016; 9(5):461-465
- 33 59. Serebrakian AT, Poulos T, Liebl H, Joseph GB, Lai A, Nevitt MC et al. Weight loss
34 over 48 months is associated with reduced progression of cartilage T2 relaxation time
35 values: data from the osteoarthritis initiative. *Journal of Magnetic Resonance*
36 *Imaging*. 2015; 41(5):1272-1280
- 37 60. Shin D. Association between metabolic syndrome, radiographic knee osteoarthritis,
38 and intensity of knee pain: results of a national survey. *Journal of Clinical*
39 *Endocrinology and Metabolism*. 2014; 99(9):3177-3183
- 40 61. Tanamas SK, Wluka AE, Davies-Tuck M, Wang Y, Strauss BJ, Proietto J et al.
41 Association of weight gain with incident knee pain, stiffness, and functional difficulties:
42 a longitudinal study. *Arthritis Care and Research*. 2013; 65(1):34-43
- 43 62. Teichtahl AJ, Wluka AE, Tanamas SK, Wang Y, Strauss BJ, Proietto J et al. Weight
44 change and change in tibial cartilage volume and symptoms in obese adults. *Annals*
45 *of the Rheumatic Diseases*. 2015; 74(6):1024-1029

- 1 63. Trofa D, Smith EL, Shah V, Shikora S. Total weight loss associated with increased
2 physical activity after bariatric surgery may increase the need for total joint
3 arthroplasty. *Surgery for Obesity and Related Diseases*. 2014; 10(2):335-339
- 4 64. Ustun I, Solmaz A, Gulcicek OB, Kara S, Albayrak R. Effects of bariatric surgery on
5 knee osteoarthritis, knee pain and quality of life in female patients. *Journal of*
6 *Musculoskeletal Neuronal Interactions*. 2019; 19(4):465-471
- 7 65. Veronese N, Stubbs B, Noale M, Solmi M, Rizzoli R, Vaona A et al. Adherence to a
8 Mediterranean diet is associated with lower incidence of frailty: A longitudinal cohort
9 study. *Clinical Nutrition*. 2018; 37(5):1492-1497
- 10 66. Vincent HK, Heywood K, Connelly J, Hurley RW. Obesity and weight loss in the
11 treatment and prevention of osteoarthritis. *Pm & R*. 2012; 4(Suppl 5):S59-67
- 12 67. Visser AW, Ioan-Facsinay A, de Mutsert R, Widya RL, Loef M, de Roos A et al.
13 Adiposity and hand osteoarthritis: the Netherlands Epidemiology of Obesity study.
14 *Arthritis Research & Therapy*. 2014; 16(1):R19
- 15 68. White-O'Connor B, Sobal J, Muncie HL, Jr. Dietary habits, weight history, and vitamin
16 supplement use in elderly osteoarthritis patients. *Journal of the American Dietetic*
17 *Association*. 1989; 89(3):378-382
- 18 69. Wluka AE, Lombard CB, Cicuttini FM. Tackling obesity in knee osteoarthritis. *Nature*
19 *Reviews Rheumatology*. 2013; 9(4):225-235
- 20 70. Yoshimura N, Muraki S, Oka H, Tanaka S, Kawaguchi H, Nakamura K et al.
21 Accumulation of metabolic risk factors such as overweight, hypertension,
22 dyslipidaemia, and impaired glucose tolerance raises the risk of occurrence and
23 progression of knee osteoarthritis: a 3-year follow-up of the ROAD study.
24 *Osteoarthritis and Cartilage*. 2012; 20(11):1217-1226
- 25 71. Zeng C, Lane NE, Li X, Wei J, Lyu H, Shao M et al. Association between bariatric
26 surgery with long-term analgesic prescription and all-cause mortality among patients
27 with osteoarthritis: a general population-based cohort study. *Osteoarthritis and*
28 *Cartilage*. 2021; 29(10):1412-1417
- 29
30
31

1 Appendices

2 Appendix A – Review protocols

3 Review protocol for the benefit of weight loss for the management of osteoarthritis in people who are overweight or obese

ID	Field	Content
0.	PROSPERO registration number	CRD42021230518
1.	Review title	What is the benefit of weight loss for the management of osteoarthritis in overweight and obese people?
2.	Review question	What is the benefit of weight loss for the management of osteoarthritis in overweight and obese people?
3.	Objective	To assess the effect of weight loss (by any means) on outcomes in people with osteoarthritis who are overweight or obese people.
4.	Searches	<p>The following databases will be searched:</p> <ul style="list-style-type: none"> • Embase • MEDLINE <p>Searches will be restricted by:</p> <ul style="list-style-type: none"> • English language • Human studies • Letters and comments are excluded <p>Other searches:</p> <ul style="list-style-type: none"> • Inclusion lists of relevant systematic reviews will be checked by the reviewer.

		<p>The searches may be re-run 6 weeks before final submission of the review and further studies retrieved for inclusion if relevant.</p> <p>The full search strategies for MEDLINE database will be published in the final review.</p>
5.	Condition or domain being studied	People, aged 16 years and over, with osteoarthritis (of any joint)
6.	Population	<p>Inclusion:</p> <ul style="list-style-type: none"> • Adults (age ≥16 years) with osteoarthritis affecting any joint • People who are overweight (BMI of 25 or over) or obese (BMI of 30 or over) <p>The population will be stratified by:</p> <ul style="list-style-type: none"> • Overweight or obese classification (as defined above) • Site of osteoarthritis: <ul style="list-style-type: none"> ○ Hip ○ Knee ○ Ankle ○ Foot ○ Toe ○ Shoulder ○ Elbow ○ Wrist ○ Hand ○ Thumb ○ Finger ○ Temporomandibular joint (TMJ) ○ Multisite

		<p>Exclusion:</p> <ul style="list-style-type: none"> • Children (age <16 years) • People with conditions that may make them susceptible to osteoarthritis or often occur alongside osteoarthritis (including: crystal arthritis, inflammatory arthritis, septic arthritis, diseases of childhood that may predispose to osteoarthritis, medical conditions presenting with joint inflammation and malignancy). • Studies with an unclear population (e.g, proportion of participants with osteoarthritis unclear) • Spinal osteoarthritis
7.	Intervention/Exposure/Test	<p>Prognostic factors:</p> <p>Weight loss by any means resulting in:</p> <ul style="list-style-type: none"> • Weight loss <5% • 5-10% • >10%
8.	Comparator/Reference standard/Confounding factors	<p>Confounding factors:</p> <ul style="list-style-type: none"> • Baseline BMI (or weight in the absence of BMI) • Baseline symptoms such as pain and/or function • Intervention (if sample selected/were randomised to various interventions) • Age
9.	Types of study to be included	<p>Non-randomised evidence, including:</p> <ol style="list-style-type: none"> 4. Secondary analyses of RCTs (stratified results by weight loss) 5. Prospective and retrospective cohort studies 6. Case control studies (if no other evidence identified) <p>Studies will only be included if all of the key confounders have been accounted for in a multivariate analysis. In the absence of multivariate analysis, studies that account for key confounders with univariate analysis or matched groups will be considered.</p>
10.	Other exclusion criteria	<ul style="list-style-type: none"> • Non-English language studies

		<ul style="list-style-type: none"> • Conference abstracts will be excluded as it is expected there will be sufficient full text published studies available <p>Abstracts will be excluded as it is expected there will be sufficient full text published studies available.</p>
11.	Context	N/A
12.	Primary outcomes (critical outcomes)	<p>Stratify by \leq/$>$3 months (longest time-point in each):</p> <ul style="list-style-type: none"> • Health-related quality of life [validated patient-reported outcomes, continuous data prioritised] • Physical function [validated patient-reported outcomes, continuous data prioritised] • Pain [validated patient-reported outcomes, continuous data prioritised] <p>The COMET database was searched and several core outcome sets were identified for specific sites of osteoarthritis (including hand, knee and hip). The committee took these into account when defining outcomes:</p> <p>https://onlinelibrary.wiley.com/doi/full/10.1002/acr.22868</p> <p>https://www.ncbi.nlm.nih.gov/pubmed/26136489</p> <p>https://www.ncbi.nlm.nih.gov/pubmed/30647185</p> <p>The committee did not include stiffness or global scores as Delphi discussions by the OMERACT group have found these to not be as important to people with osteoarthritis or clinicians. The outcomes included were universal for all groups allowing for broader comparisons.</p>
13.	Secondary outcomes (important outcomes)	<ul style="list-style-type: none"> • Psychological distress [validated patient-reported outcomes, continuous data prioritised] • Osteoarthritis flare-ups [validated patient-reported outcomes, continuous data prioritised]
14.	Data extraction (selection and coding)	<p>EndNote will be used for reference management, sifting, citations and bibliographies. All references identified by the searches and from other sources will be screened for inclusion. 10% of the abstracts will be reviewed by two reviewers, with any disagreements resolved by discussion or, if necessary, a third independent reviewer. The full text of potentially eligible studies will be retrieved and will be assessed in line with the criteria outlined above.</p> <p>EviBASE will be used for data extraction.</p>

		Study investigators may be contacted for missing data where time and resources allow.
15.	Risk of bias (quality) assessment	<p>Risk of bias will be assessed using the appropriate checklist as described in Developing NICE guidelines: the manual</p> <ul style="list-style-type: none"> • The QUIPs checklist will be used to assess risk of bias of each individual study. <p>For intervention reviews the following checklists will be used according to the study design being assessed:</p> <ul style="list-style-type: none"> • Randomised Controlled Trial: Cochrane RoB (2.0) • Non randomised study, including cohort studies: Cochrane ROBINS-I • Case control study: CASP case control checklist <p>10% of all evidence reviews are quality assured by a senior research fellow. This includes checking:</p> <ul style="list-style-type: none"> • papers were included /excluded appropriately • a sample of the data extractions • correct methods are used to synthesise data • a sample of the risk of bias assessments <p>Disagreements between the review authors over the risk of bias in particular studies will be resolved by discussion, with involvement of a third review author where necessary.</p>
16.	Strategy for data synthesis	<ul style="list-style-type: none"> • Pairwise meta-analyses will be performed using Cochrane Review Manager (RevMan5). • GRADEpro will be used to assess the quality of evidence for each outcome, taking into account individual study quality and the meta-analysis results. The 4 main quality elements (risk of bias, indirectness, inconsistency and imprecision) will be appraised for each outcome. Publication bias is tested for when there are more than 5 studies for an outcome. <p>The risk of bias across all available evidence was evaluated for each outcome using an adaptation of the 'Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox' developed by the international GRADE working group http://www.gradeworkinggroup.org/</p> <ul style="list-style-type: none"> • Where meta-analysis is not possible, data will be presented and quality assessed individually per outcome.

		<ul style="list-style-type: none"> WinBUGS will be used for network meta-analysis, if possible given the data identified. <p>Heterogeneity between studies in the effect measures will be assessed using the I^2 statistic and visual inspection. We will consider an I^2 value great than 50% as indicative of substantial heterogeneity. If significant heterogeneity is identified during meta-analysis then subgroup analysis, using subgroups predefined by the GC, will take place. If this does not explain the heterogeneity, the results will be presented using a random-effects model.</p>		
17.	Analysis of sub-groups	Study types (secondary analysis of RCTs, cohort studies, or case control studies)		
18.	Type and method of review	<input type="checkbox"/>	Intervention	
		<input type="checkbox"/>	Diagnostic	
		<input checked="" type="checkbox"/>	Prognostic	
		<input type="checkbox"/>	Qualitative	
		<input type="checkbox"/>	Epidemiologic	
		<input type="checkbox"/>	Service Delivery	
		<input type="checkbox"/>	Other (please specify)	
19.	Language	English		
20.	Country	England		
21.	Anticipated or actual start date	23/08/2019		
22.	Anticipated completion date	25/08/2021		
23.	Stage of review at time of this submission	Review stage	Started	Completed
		Preliminary searches	<input checked="" type="checkbox"/>	<input type="checkbox"/>

		Piloting of the study selection process	<input type="checkbox"/>	<input type="checkbox"/>
		Formal screening of search results against eligibility criteria	<input type="checkbox"/>	<input type="checkbox"/>
		Data extraction	<input type="checkbox"/>	<input type="checkbox"/>
		Risk of bias (quality) assessment	<input type="checkbox"/>	<input type="checkbox"/>
		Data analysis	<input type="checkbox"/>	<input type="checkbox"/>
24.	Named contact	<p>5a. Named contact National Guideline Centre</p> <p>5b Named contact e-mail [Guideline email]@nice.org.uk [Developer to check with Guideline Coordinator for email address]</p> <p>5e Organisational affiliation of the review National Institute for Health and Care Excellence (NICE) and the National Guideline Centre</p>		
25.	Review team members	<p>From the National Guideline Centre: Carlos Sharpin [Guideline lead] Julie Neilson [Senior systematic reviewer]</p>		

		George Wood [Systematic reviewer] Emma Cowles [Senior health economist] Joseph Runicles [Information specialist] Amber Hernaman [Project manager]
26.	Funding sources/sponsor	This systematic review is being completed by the National Guideline Centre which receives funding from NICE.
27.	Conflicts of interest	All guideline committee members and anyone who has direct input into NICE guidelines (including the evidence review team and expert witnesses) must declare any potential conflicts of interest in line with NICE's code of practice for declaring and dealing with conflicts of interest. Any relevant interests, or changes to interests, will also be declared publicly at the start of each guideline committee meeting. Before each meeting, any potential conflicts of interest will be considered by the guideline committee Chair and a senior member of the development team. Any decisions to exclude a person from all or part of a meeting will be documented. Any changes to a member's declaration of interests will be recorded in the minutes of the meeting. Declarations of interests will be published with the final guideline.
28.	Collaborators	Development of this systematic review will be overseen by an advisory committee who will use the review to inform the development of evidence-based recommendations in line with section 3 of Developing NICE guidelines: the manual . Members of the guideline committee are available on the NICE website: https://www.nice.org.uk/guidance/indevelopment/gid-ng10127
29.	Other registration details	
30.	Reference/URL for published protocol	
31.	Dissemination plans	NICE may use a range of different methods to raise awareness of the guideline. These include standard approaches such as: <ul style="list-style-type: none"> • notifying registered stakeholders of publication • publicising the guideline through NICE's newsletter and alerts • issuing a press release or briefing as appropriate, posting news articles on the NICE website, using social media channels, and publicising the guideline within NICE.

32.	Keywords	Adults; Prognosis; Osteoarthritis; Overweight; Obese; Weight loss	
33.	Details of existing review of same topic by same authors		
34.	Current review status	<input checked="" type="checkbox"/>	Ongoing
		<input type="checkbox"/>	Completed but not published
		<input type="checkbox"/>	Completed and published
		<input type="checkbox"/>	Completed, published and being updated
		<input type="checkbox"/>	Discontinued
35..	Additional information	N/A	
36.	Details of final publication	www.nice.org.uk	

1

2

1 **Table 9: Health economic review protocol**

Review question	All questions – health economic evidence
Objectives	To identify health economic studies relevant to any of the review questions.
Search criteria	<ul style="list-style-type: none"> • Populations, interventions and comparators must be as specified in the clinical review protocol above. • Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis). • Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.) • Unpublished reports will not be considered unless submitted as part of a call for evidence. • Studies must be in English.
Search strategy	A health economic study search will be undertaken for all years using population-specific terms and a health economic study filter – see appendix B below.
Review strategy	<p>Studies not meeting any of the search criteria above will be excluded. Studies published before 2005, abstract-only studies and studies from non-OECD countries or the USA will also be excluded.</p> <p>Studies published in 2005 or later, that were included in the previous guidelines, will be reassessed for inclusion and may be included or selectively excluded based on their relevance to the questions covered in this update and whether more applicable evidence is also identified.</p> <p>Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014).⁴⁵</p> <p>Inclusion and exclusion criteria</p> <ul style="list-style-type: none"> • If a study is rated as both ‘Directly applicable’ and with ‘Minor limitations’ then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile. • If a study is rated as either ‘Not applicable’ or with ‘Very serious limitations’ then it will usually be excluded from the guideline. If it is excluded then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile. • If a study is rated as ‘Partially applicable’, with ‘Potentially serious limitations’ or both then there is discretion over whether it should be included.

Where there is discretion

The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.

The health economist will be guided by the following hierarchies.

Setting:

- UK NHS (most applicable).
- OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).
- OECD countries with predominantly private health insurance systems (for example, Switzerland).
- Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations.

Health economic study type:

- Cost–utility analysis (most applicable).
- Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis).
- Comparative cost analysis.
- Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.

Year of analysis:

- The more recent the study, the more applicable it will be.
- Studies published in 2005 or later (including any such studies included in the previous guidelines) but that depend on unit costs and resource data entirely or predominantly from before 2005 will be rated as ‘Not applicable’.
- Studies published before 2005 (including any such studies included in the previous guidelines) will be excluded before being assessed for applicability and methodological limitations.

Quality and relevance of effectiveness data used in the health economic analysis:

- The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.

Appendix B – Literature search strategies

- What is the benefit of weight loss for the management of osteoarthritis in overweight and obese people?

The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual.⁴⁵

For more information, please see the Methodology review published as part of the accompanying documents for this guideline.

B.1 Clinical search literature search strategy

Searches were constructed by combining an Osteoarthritis population with prognostic/risk factor terms.

Table 10: Database date parameters and filters used

Database	Dates searched	Search filter used
Medline (OVID)	1946 – 17 November 2021	Exclusions (animals studies, letters, comments)
Embase (OVID)	1974 – 17 November 2021	Exclusions (animals studies, letters, comments)

Medline (Ovid) search terms

1.	exp osteoarthritis/
2.	(osteoarthriti* or osteo-arthriti* or osteoarthrotic or osteoarthros*).ti,ab.
3.	(degenerative adj2 arthritis).ti,ab.
4.	coxarthrosis.ti,ab.
5.	gonarthrosis.ti,ab.
6.	or/1-5
7.	letter/
8.	editorial/
9.	news/
10.	exp historical article/
11.	Anecdotes as Topic/
12.	comment/
13.	case report/
14.	(letter or comment*).ti.
15.	or/7-14
16.	randomized controlled trial/ or random*.ti,ab.
17.	15 not 16
18.	animals/ not humans/
19.	exp Animals, Laboratory/
20.	exp Animal Experimentation/
21.	exp Models, Animal/

22.	exp Rodentia/
23.	(rat or rats or mouse or mice or rodent*).ti.
24.	or/17-23
25.	6 not 24
26.	limit 25 to English language
27.	weight loss/
28.	(weight adj2 (los* or reduc* or manag*)).ti,ab.
29.	exp overweight/
30.	(obese or obesity or overweight or over weight or overeat* or "over eat*").ti,ab.
31.	or/27-30
32.	26 and 31

Embase (Ovid) search terms

1.	exp osteoarthritis/
2.	(osteoarthriti* or osteo-arthriti* or osteoarthrotic or osteoarthros*).ti,ab.
3.	(degenerative adj2 arthritis).ti,ab.
4.	coxarthrosis.ti,ab.
5.	gonarthrosis.ti,ab.
6.	or/1-5
7.	letter.pt. or letter/
8.	note.pt.
9.	editorial.pt.
10.	case report/ or case study/
11.	(letter or comment*).ti.
12.	or/7-11
13.	randomized controlled trial/ or random*.ti,ab.
14.	12 not 13
15.	animal/ not human/
16.	nonhuman/
17.	exp Animal Experiment/
18.	exp Experimental Animal/
19.	animal model/
20.	exp Rodent/
21.	(rat or rats or mouse or mice).ti.
22.	or/14-21
23.	6 not 22
24.	Limit 23 to English language
25.	body weight loss/
26.	(weight adj2 (los* or reduc* or manag*)).ti,ab.
27.	exp obesity/
28.	(obese or obesity or overweight or over weight or overeat* or "over eat*").ti,ab.
29.	or/25-28
30.	24 and 29

B.2 Health Economics literature search strategy

Health economic evidence was identified by conducting a broad search relating to a Gout population in NHS Economic Evaluation Database (NHS EED – this ceased to be updated after March 2015) and the Health Technology Assessment database (HTA – this ceased to be updated after March 2018). NHS EED and HTA databases are hosted by the Centre for Research and Dissemination (CRD). Additional searches were run on Medline and Embase for health economics studies and quality of life studies. Searches for quality of life studies were run for general information.

Table 11: Database date parameters and filters used

Database	Dates searched	Search filter used
Medline	1 January 2014 – 17 November 2021	Health economics studies Quality of life studies Exclusions (animals studies, letters, comments)
Embase	1 January 2014 – 17 November 2021	Health economics studies Quality of life studies Exclusions (animals studies, letters, comments)
Centre for Research and Dissemination (CRD)	HTA - Inception – 31 March 2018 NHSEED - Inception to 31 March 2015	None

Medline (Ovid) search terms

1.	exp osteoarthritis/
2.	(osteoarthritis* or osteo-arthritis* or osteoarthrotic or osteoarthros*).ti,ab.
3.	(degenerative adj2 arthritis).ti,ab.
4.	coxarthrosis.ti,ab.
5.	gonarthrosis.ti,ab.
6.	or/1-5
7.	letter/
8.	editorial/
9.	news/
10.	exp historical article/
11.	Anecdotes as Topic/
12.	comment/
13.	case report/
14.	(letter or comment*).ti.
15.	or/7-14
16.	randomized controlled trial/ or random*.ti,ab.
17.	15 not 16
18.	animals/ not humans/

19.	exp Animals, Laboratory/
20.	exp Animal Experimentation/
21.	exp Models, Animal/
22.	exp Rodentia/
23.	(rat or rats or mouse or mice or rodent*).ti.
24.	or/17-23
25.	6 not 24
26.	limit 25 to English language
27.	Economics/
28.	Value of life/
29.	exp "Costs and Cost Analysis"/
30.	exp Economics, Hospital/
31.	exp Economics, Medical/
32.	Economics, Nursing/
33.	Economics, Pharmaceutical/
34.	exp "Fees and Charges"/
35.	exp Budgets/
36.	budget*.ti,ab.
37.	cost*.ti.
38.	(economic* or pharmaco?economic*).ti.
39.	(price* or pricing*).ti,ab.
40.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
41.	(financ* or fee or fees).ti,ab.
42.	(value adj2 (money or monetary)).ti,ab.
43.	or/27-42
44.	quality-adjusted life years/
45.	sickness impact profile/
46.	(quality adj2 (wellbeing or well being)).ti,ab.
47.	sickness impact profile.ti,ab.
48.	disability adjusted life.ti,ab.
49.	(qal* or qtime* or qwb* or daly*).ti,ab.
50.	(euroqol* or eq5d* or eq 5*).ti,ab.
51.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.
52.	(hui or hui1 or hui2 or hui3).ti,ab.
53.	(health* year* equivalent* or hye or hyes).ti,ab.
54.	discrete choice*.ti,ab.
55.	rosser.ti,ab.
56.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
57.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.

58.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
59.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.
60.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.
61.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.
62.	or/44-61
63.	26 and (43 or 62)

Embase (Ovid) search terms

1.	exp osteoarthritis/
2.	(osteoarthriti* or osteo-arthriti* or osteoarthrotic or osteoarthros*).ti,ab.
3.	(degenerative adj2 arthritis).ti,ab.
4.	coxarthrosis.ti,ab.
5.	gonarthrosis.ti,ab.
6.	or/1-5
7.	letter.pt. or letter/
8.	note.pt.
9.	editorial.pt.
10.	case report/ or case study/
11.	(letter or comment*).ti.
12.	or/7-11
13.	randomized controlled trial/ or random*.ti,ab.
14.	12 not 13
15.	animal/ not human/
16.	nonhuman/
17.	exp Animal Experiment/
18.	exp Experimental Animal/
19.	animal model/
20.	exp Rodent/
21.	(rat or rats or mouse or mice or rodent*).ti.
22.	or/14-21
23.	6 not 22
24.	Limit 23 to English language
25.	health economics/
26.	exp economic evaluation/
27.	exp health care cost/
28.	exp fee/
29.	budget/
30.	funding/
31.	budget*.ti,ab.
32.	cost*.ti.


33.	(economic* or pharmaco?economic*).ti.
34.	(price* or pricing*).ti,ab.
35.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
36.	(financ* or fee or fees).ti,ab.
37.	(value adj2 (money or monetary)).ti,ab.
38.	or/25-37
39.	quality adjusted life year/
40.	"quality of life index"/
41.	short form 12/ or short form 20/ or short form 36/ or short form 8/
42.	sickness impact profile/
43.	(quality adj2 (wellbeing or well being)).ti,ab.
44.	sickness impact profile.ti,ab.
45.	disability adjusted life.ti,ab.
46.	(qal* or qtime* or qwb* or daly*).ti,ab.
47.	(euroqol* or eq5d* or eq 5*).ti,ab.
48.	(qol* or hqi* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
49.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.
50.	(hui or hui1 or hui2 or hui3).ti,ab.
51.	(health* year* equivalent* or hye or hyes).ti,ab.
52.	discrete choice*.ti,ab.
53.	rosser.ti,ab.
54.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
55.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.
56.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
57.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.
58.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.
59.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.
60.	or/39-59
61.	24 and (38 or 60)

NHS EED and HTA (CRD) search terms

#1.	MeSH DESCRIPTOR Osteoarthritis EXPLODE ALL TREES
#2.	((osteoarthritis* or osteo-arthritis* or osteoarthrotic or osteoarthros*))
#3.	((degenerative adj2 arthritis))
#4.	(coxarthrosis)
#5.	(gonarthrosis)
#6.	#1 OR #2 OR #3 OR #4 OR #5
#7.	(#6) IN NHSEED
#8.	(#6) IN HTA

Appendix C – Prognostic evidence study selection

Figure 1: Flow chart of clinical study selection for the review of the benefit of weight loss for people with osteoarthritis who are overweight or obese



Appendix D – Prognostic evidence

Reference	Atukorala 2016 ³
Study type and analysis	<p>Prospective cohort study</p> <p>Repeated-measures of analysis of variance, controlling for sex, age, body mass index and KOOS</p> <p>Australia, rural and urban settings</p>
Number of participants and characteristics	<p>N=3827 recruited, 2098 completed the follow up, 715 incomplete data or hip osteoarthritis, 1383 included</p> <p>Stable weight, n=110 (54 were obese)</p> <p>Loss of ≤5% of baseline weight (two groups)</p> <ul style="list-style-type: none"> - Loss of ≤2.5% of baseline weight, n=79 - Loss of 2.5-5% of baseline weight, n=224 <p>Loss of 5-10% of baseline weight (two groups)</p> <ul style="list-style-type: none"> - Loss of 5-7.5% of baseline weight, n=332 - Loss of 7.5-10% of baseline weight, n=317 <p>Loss of ≥10% of baseline weight, n=431</p> <p>People with symptomatic knee osteoarthritis with a mean BMI of 34.39 (5.17) kg/m² (1130/81.7% were obese at baseline) who were enrolled in a specialized knee and hip osteoarthritis management program that focuses on weight loss (i.e., the Osteoarthritis Health Weight for Life Program). The OAHWFL program systematically implements a number of core nonsurgical osteoarthritis best practice treatment recommendations, including targeting >5% weight loss for overweight individuals, land- and water-based aerobic exercise (walking and swimming), muscle strengthening, and self-management and education strategies. The program utilizes a step-by-step approach that consists of 3 phases, carried out over 18 weeks. Each 6-week phase includes a portion control eating plan (including KicStart very low calorie diet meal replacements); an activity plan and physiotherapist-developed strength, balance and mobility exercises; a personalized online symptom, progress and satisfaction tracking (phone and mail alternatives also available) activity; and 2-way personal motivation, support and advice via phone, short message service/text message, e-mail, message board, and mail.</p> <p>Inclusion criteria:</p> <p>Participants in the OAHWFL program who fulfilled the 1986 American College of Rheumatology clinical criteria for classification of knee osteoarthritis. People had a current or historical diagnosis of knee osteoarthritis supported by radiology (e.g. on radiographs or magnetic resonance imaging) or by an incidental finding from a previous arthroscopy and a body mass index >28kg/m². In addition, all participants had, according to medical opinion, knee osteoarthritis symptoms that required (or were likely to in the foreseeable future)</p>

Reference	Atukorala 2016 ³
	<p>referral to an orthopaedic surgeon for evaluation for a knee joint replacement procedure. In these persons' weight loss, improved fitness and muscle strength prior to surgery was desirable.</p> <p>Exclusion criteria: No additional information.</p> <p>Values listed below are presented as mean (SD) or number (%)</p> <ul style="list-style-type: none"> • Age: 64.0 (8.7) years • Male/female: 402/981 (29.1%/70.9%) • Weight: 95.12 (17.2) kg • Height: 1.66 (0.09) meters • BMI: 34.39 (5.17) kg/m² • Obesity (BMI ≥30kg/m²) at baseline: 1130 (81.7%) • Obesity (BMI ≥30kg/m²) at 18 weeks: 772 (56.3%) • Baseline KOOS pain subscale (0-100, high is good): 56.3 (16.8) • Baseline KOOS function in daily living subscale (WOMAC function) (0-100, high is good): 59.5 (18.3) • Baseline KOOS other symptoms subscale (0-100, high is good): 54.3 (17.7) • Baseline KOOS function in sport/recreation subscale (0-100, high is good): 27.6 (24.2) • KOOS knee related quality of life subscale (0-100, high is good): 35.1 (18.4) <p>Population source: Consecutive persons enrolled in the OAHWFL program and fulfilling the eligibility criteria</p>
Prognostic variable	<p>Loss of ≤5% of baseline weight Loss of 5-10% of baseline weight Loss of ≥10% of baseline weight</p>
Confounders	<p>Repeated-measures of analysis of variance (beta-coefficient reported for one outcome)</p> <p>Factors included in adjusted analysis: Sex, age, BMI, KOOS scores.</p>
Outcomes and effect sizes	<p>Health-related quality of life (difference in KOOS quality of life subscale after weight loss) Pain (difference in KOOS pain subscale after weight loss) Physical function (difference in KOOS function in daily living subscale [WOMAC function score] after weight loss)</p>

Reference	Atukorala 2016 ³
	<p><u>Health-related quality of life – Difference in KOOS quality of life subscale after weight loss (0-100, high is good)</u></p> <p>Loss of ≤5% of baseline weight (two groups) – mean (SD) – 8.7 (17.4)</p> <ul style="list-style-type: none"> - Loss of ≤2.5% of baseline weight, n=79 – mean (SD) – 5.3 (17.6) - Loss of 2.5-5% of baseline weight, n=224 – mean (SD) – 9.9 (17.1) <p>Loss of 5-10% of baseline weight (two groups) – mean (SD) – 12.1 (24.9)</p> <ul style="list-style-type: none"> - Loss of 5-7.5% of baseline weight, n=332 – mean (SD) – 11.5 (25.1) - Loss of 7.5-10% of baseline weight, n=317 – mean (SD) – 12.7 (24.6) <p>Loss of ≥10% of baseline weight, n=431 – mean (SD) – 16.2 (18.2)</p> <p><u>Pain – Difference in KOOS pain subscale after weight loss (0-100, high is good)</u></p> <p>Loss of ≤5% of baseline weight (two groups) – mean (SD) – 8.9 (16.0)</p> <ul style="list-style-type: none"> - Loss of ≤2.5% of baseline weight, n=79 – mean (SD) – 6.1 (13.0) - Loss of 2.5-5% of baseline weight, n=224 – mean (SD) – 9.9 (16.8) <p>Loss of 5-10% of baseline weight (two groups) – mean (SD) – 12.6 (16.2)</p> <ul style="list-style-type: none"> - Loss of 5-7.5% of baseline weight, n=332 – mean (SD) – 12.0 (17.1) - Loss of 7.5-10% of baseline weight, n=317 – mean (SD) – 13.3 (15.1) <p>Loss of ≥10% of baseline weight, n=431 – mean (SD) – 16.7 (16.1)</p> <p><u>Physical function – Difference in KOOS function in daily living subscale [WOMAC function score] after weight loss (0-100, high is good)</u></p> <p>Loss of ≤5% of baseline weight (two groups) – mean (SD) – 8.6 (14.4)</p> <ul style="list-style-type: none"> - Loss of ≤2.5% of baseline weight, n=79 – mean (SD) – 7.8 (13.3) - Loss of 2.5-5% of baseline weight, n=224 – mean (SD) – 8.9 (14.7) <p>Loss of 5-10% of baseline weight (two groups) – mean (SD) – 12.8 (16.1)</p> <ul style="list-style-type: none"> - Loss of 5-7.5% of baseline weight, n=332 – mean (SD) – 12.0 (16.7) - Loss of 7.5-10% of baseline weight, n=317 – mean (SD) – 13.6 (15.5) <p>Loss of ≥10% of baseline weight, n=431 – mean (SD) – 17.4 (16.3)</p> <p>Follow up: 18 weeks</p>
Comments	<u>Health-related quality of life – Difference in KOOS quality of life subscale after weight loss (0-100, high is good)</u>

Reference	Atukorala 2016 ³																																																
	<p>Risk of bias:</p> <table> <tr> <td>1. Study participation</td> <td>HIGH</td> </tr> <tr> <td>2. Study attrition</td> <td>HIGH</td> </tr> <tr> <td>3. Prognostic factor measurement</td> <td>LOW</td> </tr> <tr> <td>4. Outcome Measurement</td> <td>LOW</td> </tr> <tr> <td>5. Study confounding</td> <td>LOW</td> </tr> <tr> <td>6. Statistical analysis</td> <td>LOW</td> </tr> <tr> <td>7. Other risk of bias</td> <td>LOW</td> </tr> <tr> <td>OVERALL RISK OF BIAS</td> <td>VERY HIGH</td> </tr> </table> <p><u>Pain – Difference in KOOS pain subscale after weight loss (0-100, high is good)</u></p> <p>Risk of bias:</p> <table> <tr> <td>1. Study participation</td> <td>HIGH</td> </tr> <tr> <td>2. Study attrition</td> <td>HIGH</td> </tr> <tr> <td>3. Prognostic factor measurement</td> <td>LOW</td> </tr> <tr> <td>4. Outcome Measurement</td> <td>LOW</td> </tr> <tr> <td>5. Study confounding</td> <td>LOW</td> </tr> <tr> <td>6. Statistical analysis</td> <td>LOW</td> </tr> <tr> <td>7. Other risk of bias</td> <td>LOW</td> </tr> <tr> <td>OVERALL RISK OF BIAS</td> <td>VERY HIGH</td> </tr> </table> <p><u>Physical function – Difference in KOOS function in daily living subscale [WOMAC function score] after weight loss (0-100, high is good)</u></p> <p>Risk of bias:</p> <table> <tr> <td>1. Study participation</td> <td>HIGH</td> </tr> <tr> <td>2. Study attrition</td> <td>HIGH</td> </tr> <tr> <td>3. Prognostic factor measurement</td> <td>LOW</td> </tr> <tr> <td>4. Outcome Measurement</td> <td>LOW</td> </tr> <tr> <td>5. Study confounding</td> <td>LOW</td> </tr> <tr> <td>6. Statistical analysis</td> <td>LOW</td> </tr> <tr> <td>7. Other risk of bias</td> <td>LOW</td> </tr> <tr> <td>OVERALL RISK OF BIAS</td> <td>VERY HIGH</td> </tr> </table>	1. Study participation	HIGH	2. Study attrition	HIGH	3. Prognostic factor measurement	LOW	4. Outcome Measurement	LOW	5. Study confounding	LOW	6. Statistical analysis	LOW	7. Other risk of bias	LOW	OVERALL RISK OF BIAS	VERY HIGH	1. Study participation	HIGH	2. Study attrition	HIGH	3. Prognostic factor measurement	LOW	4. Outcome Measurement	LOW	5. Study confounding	LOW	6. Statistical analysis	LOW	7. Other risk of bias	LOW	OVERALL RISK OF BIAS	VERY HIGH	1. Study participation	HIGH	2. Study attrition	HIGH	3. Prognostic factor measurement	LOW	4. Outcome Measurement	LOW	5. Study confounding	LOW	6. Statistical analysis	LOW	7. Other risk of bias	LOW	OVERALL RISK OF BIAS	VERY HIGH
1. Study participation	HIGH																																																
2. Study attrition	HIGH																																																
3. Prognostic factor measurement	LOW																																																
4. Outcome Measurement	LOW																																																
5. Study confounding	LOW																																																
6. Statistical analysis	LOW																																																
7. Other risk of bias	LOW																																																
OVERALL RISK OF BIAS	VERY HIGH																																																
1. Study participation	HIGH																																																
2. Study attrition	HIGH																																																
3. Prognostic factor measurement	LOW																																																
4. Outcome Measurement	LOW																																																
5. Study confounding	LOW																																																
6. Statistical analysis	LOW																																																
7. Other risk of bias	LOW																																																
OVERALL RISK OF BIAS	VERY HIGH																																																
1. Study participation	HIGH																																																
2. Study attrition	HIGH																																																
3. Prognostic factor measurement	LOW																																																
4. Outcome Measurement	LOW																																																
5. Study confounding	LOW																																																
6. Statistical analysis	LOW																																																
7. Other risk of bias	LOW																																																
OVERALL RISK OF BIAS	VERY HIGH																																																

Reference	Atukorala 2016 ³
	Indirectness: No indirectness noted

Reference	Riddle 2013 ⁵⁵
Study type and analysis	<p>Prospective cohort study</p> <p>Regression analysis adjusting for baseline symptoms, sex, depression and number of comorbidities. Baseline values of age and weight stated and reported to be similar at baseline between different weight categories.</p> <p>United States of America, data from two observational trial cohorts the Multicenter Osteoarthritis study (MOST) and Osteoarthritis Initiative (OAI).</p> <p>The MOST study is comprised of 4 cooperative grants (AG18820, AG18832, AG18947, AG19069) funded by the NIH. The OAI is a public-private partnership comprised of 5 contracts (N01-AR-2-2258, N01-AR-2-2250, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262) funded by the NIH. Private funding partners include Merck, Novartis, GlaxoSmithKline, and Pfizer. Private sector funding for the OAI is managed by the Foundation for the NIH.</p>
Number of participants and characteristics	<p>N=1785 combined baseline (OAI included 976, MOST included 809), 1410 complete weight data at baseline and follow up, 375 missing weight data at follow up</p> <p>Unclear if overweight or obese, will be considered as overweight for the analysis</p> <p>Stable weight (4.9% reduction to 4.9% gain), n=940</p> <p>5-9.9% reduction, n=171</p> <p>≥10% reduction, n=82</p> <p>5-9.9% gain (not included in the analysis), n=148</p> <p>≥10% gain (not included in the analysis), n=51</p> <p>People enrolled in the OAI and MOST studies (studies looking at the development of knee osteoarthritis in high risk populations) who developed knee osteoarthritis. For the OAI study, people were between the ages of 45 and 79 years and were recruited from communities in and around 4 clinical sites: the University of Maryland School of Medicine in Baltimore, Maryland, the Ohio State University in Columbus, Ohio, the University of Pittsburgh in Pittsburgh, Pennsylvania, and the Memorial Hospital of Rhode Island in Pawtucket, Rhode Island. For the MOST study people were aged 50-79 years and were recruited from communities in and around 2 clinical sites: the University of Iowa in Iowa City, Iowa, and the University of Alabama, Birmingham in Birmingham, Alabama.</p> <p>Inclusion criteria:</p> <p>Radiographic tibiofemoral knee osteoarthritis, defined as definite osteophytes (OARSI atlas grade 1-3 in the OAI or Kellgren Lawrence grade 2 or higher in the MOST study) as measured on a standardized fixed-flexion radiograph; a WOMAC pain scale score of 4 or higher; a WOMAC physical function score of 9 or higher; no knee replacement surgery during the follow up period.</p> <p>Exclusion criteria:</p>

Reference	Riddle 2013 ⁵⁵
	<p>No additional information.</p> <p>Values listed below are presented as mean (SD) or number (%) (taken from complete weight data at baseline and followup)</p> <ul style="list-style-type: none"> • Age: 62.73 (8.62) years • Male/female: 529/881 (37.5%/62.5%) • African American: 360 (25.5%) • Marital status: <ul style="list-style-type: none"> ○ Married: 65.5% ○ Widowed: 10.6% ○ Divorced: 14.9% ○ Separated: 1.9% ○ Never married: 7.0% • Education: <ul style="list-style-type: none"> ○ Less than high school diploma: 6.2% ○ High school diploma: 23.2% ○ At least some college: 70.6% • Comorbidity: 0.57 (0.95) • Weight: 89.62 (18.6) kg • Current smoker: 9.0% • Center for Epidemiologic Studies Depression Scale – Percent depressed: 17.7% • Baseline WOMAC pain score (0-20, high is poor): 7.83 (3.06) • Baseline WOMAC function score (0-68, high is poor): 25.12 (10.14) <p>Population source: Participants in the MOST and OAI studies who developed osteoarthritis and fulfilling the eligibility criteria</p>
Prognostic variable	<p>Loss of ≤5% of baseline weight Loss of 5-10% of baseline weight Loss of ≥10% of baseline weight</p>
Confounders	<p>Two regression models were used to adjust for baseline symptoms, sex, depression and number of comorbidities. Reports that “the distributions of dependent variables approximated a normal distribution, and for each dependent variable, the variances among the % weight categories did not differ statistically”. The dependent variables included baseline weight and age.</p>

Reference	Riddle 2013 ⁵⁵																		
Outcomes and effect sizes	<p>Factors included in adjusted analysis: Baseline symptoms, sex, depression, number of comorbidities Factors with evidence to indicate they were matched between groups at baseline: Baseline weight, age</p> <p>Pain (difference in WOMAC pain score after weight change) Physical function (difference in WOMAC function score after weight change)</p> <p><u>Pain – Difference in WOMAC pain score after weight change (0-20, high is poor)</u> Loss of 4.9% to gain of 4.9% of baseline weight – mean (SD) – -1.09 (3.86) Loss of 5-9.9% of baseline weight – mean (SD) – -0.99 (4.34) Loss of ≥10% of baseline weight, n=431 – mean (SD) – -2.05 (4.60)</p> <p><u>Physical function – Difference in WOMAC function score after weight change (0-68, high is poor)</u> Loss of 4.9% to gain of 4.9% of baseline weight – mean (SD) – -2.78 (11.82) Loss of 5-9.9% of baseline weight – mean (SD) – -3.34 (12.62) Loss of ≥10% of baseline weight, n=431 – mean (SD) – -7.50 (13.24)</p> <p>Follow up: 30 months</p>																		
Comments	<p><u>Pain – Difference in WOMAC pain score after weight change (0-20, high is poor)</u> Risk of bias:</p> <table border="0"> <tr> <td>1. Study participation</td> <td>LOW</td> </tr> <tr> <td>2. Study attrition</td> <td>HIGH</td> </tr> <tr> <td>3. Prognostic factor measurement</td> <td>LOW</td> </tr> <tr> <td>4. Outcome Measurement</td> <td>LOW</td> </tr> <tr> <td>5. Study confounding</td> <td>HIGH</td> </tr> <tr> <td>6. Statistical analysis</td> <td>LOW</td> </tr> <tr> <td>7. Other risk of bias</td> <td>LOW</td> </tr> <tr> <td>OVERALL RISK OF BIAS</td> <td>VERY HIGH</td> </tr> </table> <p><u>Physical function – Difference in WOMAC function score after weight change (0-68, high is poor)</u> Risk of bias:</p> <table border="0"> <tr> <td>1. Study participation</td> <td>LOW</td> </tr> </table>	1. Study participation	LOW	2. Study attrition	HIGH	3. Prognostic factor measurement	LOW	4. Outcome Measurement	LOW	5. Study confounding	HIGH	6. Statistical analysis	LOW	7. Other risk of bias	LOW	OVERALL RISK OF BIAS	VERY HIGH	1. Study participation	LOW
1. Study participation	LOW																		
2. Study attrition	HIGH																		
3. Prognostic factor measurement	LOW																		
4. Outcome Measurement	LOW																		
5. Study confounding	HIGH																		
6. Statistical analysis	LOW																		
7. Other risk of bias	LOW																		
OVERALL RISK OF BIAS	VERY HIGH																		
1. Study participation	LOW																		

Reference	Riddle 2013 ⁵⁵
	2. Study attrition HIGH
	3. Prognostic factor measurement LOW
	4. Outcome Measurement LOW
	5. Study confounding HIGH
	6. Statistical analysis LOW
	7. Other risk of bias LOW
	OVERALL RISK OF BIAS VERY HIGH
	Indirectness: <ul style="list-style-type: none">• Confounders: the analysis did not clearly adjust for baseline weight/BMI and age. However, they stated that the groups were matched therefore the study was included. This could be indirect evidence but will be adjusted for in risk of bias section instead to avoid reduction in quality twice for the same reason.

Appendix E – Forest plots

E.1 People with knee osteoarthritis who are obese – Loss of 5-10% of baseline weight compared to loss of <5% of baseline weight

Figure 2: Quality of life (KOOS, 0-100, high is good, change score) at >3 months




Figure 3: Pain (KOOS, 0-100, high is good, change score) at >3 months





Figure 4: Physical function (KOOS, 0-100, high is good, change score) at >3 months



E.2 People with knee osteoarthritis who are obese – Loss of >10% of baseline weight compared to loss of <5% of baseline weight

Figure 5: Quality of life (KOOS, 0-100, high is good, change score) at >3 months




Figure 6: Pain (KOOS, 0-100, high is good, change score) at >3 months





Figure 7: Physical function (KOOS, 0-100, high is good, change score) at >3 months



E.3 People with knee osteoarthritis who are obese – Loss of >10% of baseline weight compared to loss of 5-10% of baseline weight

Figure 8: Quality of life (KOOS, 0-100, high is good, change score) at >3 months




Figure 9: Pain (KOOS, 0-100, high is good, change score) at >3 months





Figure 10: Physical function (KOOS, 0-100, high is good, change score) at >3 months



E.4 People with knee osteoarthritis where their BMI classification before the study is unclear (assumed overweight [BMI 25-30] for the analysis) – Loss of 5-10% of baseline weight compared to loss of <5% of baseline weight

Figure 11: Pain (WOMAC, 0-20, high is poor, change score) at >3 months





Figure 12: Physical function (WOMAC, 0-68, high is poor, change score) at >3 months



E.5 People with knee osteoarthritis where their BMI classification before the study is unclear (assumed overweight [BMI 25-30] for the analysis) – Loss of >10% of baseline weight compared to loss of <5% of baseline weight

Figure 13: Pain (WOMAC, 0-20, high is poor, change score) at >3 months





Figure 14: Physical function (WOMAC, 0-68, high is poor, change score) at >3 months



E.6 People with knee osteoarthritis where their BMI classification before the study is unclear (assumed overweight [BMI 25-30] for the analysis) – Loss of >10% of baseline weight compared to loss of 5-10% of baseline weight

Figure 15: Pain (WOMAC, 0-20, high is poor, change score) at >3 months





Figure 16: Physical function (WOMAC, 0-68, high is poor, change score) at >3 months



Appendix F – GRADE tables

F.1 People with knee osteoarthritis who are obese – Loss of 5-10% of baseline weight compared to loss of <5% of baseline weight

Table 12: Clinical evidence profile: loss of 5-10% of baseline weight compared to loss of <5% of baseline weight in people with knee osteoarthritis who are obese

Certainty assessment							No of patients		Effect		Certainty	Importance
No of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	loss of 5-10% of baseline weight	loss of <5% of baseline weight	Relative (95% CI)	Absolute (95% CI)		

Quality of life (KOOS, 0-100, high is good, change score) at >3 months (follow up: 18 weeks; assessed with: KOOS; Scale from: 0 to 100)

1	cohort studies	very serious ^a	not serious	not serious	not serious	none	649	303	-	MD 3.4 higher (0.66 higher to 6.14 higher)	⊕⊕○○ LOW	CRITICAL
---	----------------	---------------------------	-------------	-------------	-------------	------	-----	-----	---	---	-------------	----------

Pain (KOOS, 0-100, high is good, change score) at >3 months (follow up: 18 weeks; assessed with: KOOS; Scale from: 0 to 100)

1	cohort studies	very serious ^a	not serious	not serious	not serious	none	649	303	-	3.7 higher (1.51 higher to 5.89 higher)	⊕⊕○○ LOW	CRITICAL
---	----------------	---------------------------	-------------	-------------	-------------	------	-----	-----	---	--	-------------	----------

Physical function (KOOS, 0-100, high is good, change score) at >3 months (follow up: 18 weeks; assessed with: KOOS; Scale from: 0 to 100)

1	cohort studies	very serious ^a	not serious	not serious	not serious	none	649	303	-	4.2 higher (2.16 higher to 6.24 higher)	⊕⊕○○ LOW	CRITICAL
---	----------------	---------------------------	-------------	-------------	-------------	------	-----	-----	---	--	-------------	----------

CI: Confidence interval; MD: Mean difference

Explanations

a. Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

F.2 People with knee osteoarthritis who are obese – Loss of >10% of baseline weight compared to loss of <5% of baseline weight

Table 13: Clinical evidence profile: loss of >10% of baseline weight compared to loss of <5% of baseline weight in people with knee osteoarthritis who are obese

Certainty assessment							No of patients		Effect		Certainty	Importance
No of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	loss of >10% of baseline weight	loss of <5% of baseline weight	Relative (95% CI)	Absolute (95% CI)		

Quality of life (KOOS, 0-100, high is good, change score) at >3 months (follow up: 18 weeks; assessed with: KOOS; Scale from: 0 to 100)

1	cohort studies	very serious ^a	not serious	not serious	not serious	none	431	303	-	MD 7.5 higher (4.89 higher to 10.11 higher)	⊕⊕○○ LOW	CRITICAL
---	----------------	---------------------------	-------------	-------------	-------------	------	-----	-----	---	--	-------------	----------

Pain (KOOS, 0-100, high is good, change score) at >3 months (follow up: 18 weeks; assessed with: KOOS; Scale from: 0 to 100)

1	cohort studies	very serious ^a	not serious	not serious	not serious	none	431	303	-	MD 7.8 higher (5.44 higher to 10.16 higher)	⊕⊕○○ LOW	CRITICAL
---	----------------	---------------------------	-------------	-------------	-------------	------	-----	-----	---	--	-------------	----------

Physical function (KOOS, 0-100, high is good, change score) at >3 months (follow up: 18 weeks; assessed with: KOOS; Scale from: 0 to 100)

1	cohort studies	very serious ^a	not serious	not serious	not serious	none	431	303	-	MD 8.8 higher (6.56 higher to 11.04 higher)	⊕⊕○○ LOW	CRITICAL
---	----------------	---------------------------	-------------	-------------	-------------	------	-----	-----	---	--	-------------	----------

CI: Confidence interval; MD: Mean difference

Explanations

a. Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

F.3 People with knee osteoarthritis who are obese – Loss of >10% of baseline weight compared to loss of 5-10% of baseline weight

Table 14: Clinical evidence profile: loss of >10% of baseline weight compared to loss of 5-10% of baseline weight in people with knee osteoarthritis who are obese

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	loss of >10% of baseline weight	loss of 5-10% of baseline weight	Relative (95% CI)	Absolute (95% CI)		
Quality of life (KOOS, 0-100, high is good, change score) at >3 months (follow up: 18 weeks; assessed with: KOOS; Scale from: 0 to 100)												
1	cohort studies	very serious ^a	not serious	not serious	not serious	none	431	649	-	MD 4.1 higher (1.53 higher to 6.67 higher)	⊕⊕○○ LOW	CRITICAL
Pain (KOOS, 0-100, high is good, change score) at >3 months (follow up: 18 weeks; assessed with: KOOS; Scale from: 0 to 100)												
1	cohort studies	very serious ^a	not serious	not serious	not serious	none	431	649	-	4.1 higher (2.13 higher to 6.07 higher)	⊕⊕○○ LOW	CRITICAL
Physical function (KOOS, 0-100, high is good, change score) at >3 months (follow up: 18 weeks; assessed with: KOOS; Scale from: 0 to 100)												
1	cohort studies	very serious ^a	not serious	not serious	not serious	none	431	649	-	4.6 higher (2.62 higher to 6.58 higher)	⊕⊕○○ LOW	CRITICAL

CI: Confidence interval; MD: Mean difference

Explanations

a. Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

F.4 People with knee osteoarthritis where their BMI classification before the study is unclear (assumed overweight [BMI 25-30] for the analysis) – Loss of 5-10% of baseline weight compared to loss of <5% of baseline weight

Table 15: Clinical evidence profile: loss of 5-10% of baseline weight compared to loss of <5% of baseline weight in people with knee osteoarthritis and an unclear BMI classification

Certainty assessment							No of patients		Effect		Certainty	Importance
No of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	loss of 5-10% of baseline weight	loss of <5% of baseline weight	Relative (95% CI)	Absolute (95% CI)		
Pain (WOMAC, 0-20, high is poor, change score) at >3 months (follow up: 30 months; assessed with: WOMAC; Scale from: 0 to 20)												
1	cohort studies	very serious ^a	not serious	not serious	serious ^b	none	171	940	-	MD 0.1 higher (0.6 lower to 0.8 higher)	⊕○○○ VERY LOW	CRITICAL
Physical function (WOMAC, 0-68, high is poor, change score) at >3 months (follow up: 30 months; assessed with: WOMAC; Scale from: 0 to 68)												
1	cohort studies	very serious ^a	not serious	not serious	serious ^b	none	171	940	-	MD 0.56 lower (2.6 lower to 1.48 higher)	⊕○○○ VERY LOW	CRITICAL

CI: Confidence interval; MD: Mean difference

Explanations

a. Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

b. Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

F.5 People with knee osteoarthritis where their BMI classification before the study is unclear (assumed overweight [BMI 25-30] for the analysis) – Loss of >10% of baseline weight compared to loss of <5% of baseline weight

Table 16: Clinical evidence profile: loss of >10% of baseline weight compared to loss of <5% of baseline weight in people with knee osteoarthritis and an unclear BMI classification

Certainty assessment							No of patients		Effect		Certainty	Importance
No of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	loss of >10% of baseline weight	loss of <5% of baseline weight	Relative (95% CI)	Absolute (95% CI)		
Pain (WOMAC, 0-20, high is poor, change score) at >3 months (follow up: 30 months; assessed with: WOMAC; Scale from: 0 to 20)												
1	cohort studies	very serious ^a	not serious	not serious	serious ^b	none	82	940	-	MD 0.96 lower (1.99 lower to 0.07 higher)	⊕○○○ VERY LOW	CRITICAL
Physical function (WOMAC, 0-20, high is poor, change score) at >3 months (follow up: 30 months; assessed with: WOMAC; Scale from: 0 to 68)												
1	cohort studies	very serious ^a	not serious	not serious	not serious	none	82	940	-	MD 4.72 lower (7.68 lower to 1.76 lower)	⊕⊕○○ LOW	CRITICAL

CI: Confidence interval; MD: Mean difference

Explanations

a. Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

b. Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

F.6 People with knee osteoarthritis where their BMI classification before the study is unclear (assumed overweight [BMI 25-30] for the analysis) – Loss of >10% of baseline weight compared to loss of 5-10% of baseline weight

Table 17: Clinical evidence profile: loss of >10% of baseline weight compared to loss of 5-10% of baseline weight in people with knee osteoarthritis and an unclear BMI classification

Certainty assessment							No of patients		Effect		Certainty	Importance
No of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	loss of >10% of baseline weight	loss of 5-10% of baseline weight	Relative (95% CI)	Absolute (95% CI)		
Pain (WOMAC, 0-20, high is poor, change score) at >3 months (follow up: 30 months; assessed with: WOMAC; Scale from: 0 to 20)												
1	cohort studies	very serious ^a	not serious	not serious	serious ^b	none	82	171	-	MD 1.06 lower (2.25 lower to 0.13 higher)	⊕○○○ VERY LOW	CRITICAL
Physical function (WOMAC, 0-68, high is poor, change score) at >3 months (follow up: 30 months; assessed with: WOMAC; Scale from: 0 to 68)												
1	cohort studies	very serious ^a	not serious	not serious	not serious	none	82	171	-	MD 4.16 lower (7.59 lower to 0.73 lower)	⊕⊕○○ LOW	CRITICAL


CI: Confidence interval; MD: Mean difference

Explanations

a. Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

b. Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

Appendix G – Economic evidence study selection



(a) Non-relevant population, intervention, comparison, design or setting; non-English language.

(b) Two articles identified were applicable to Q3.1 and Q3.3, for the purposes of this diagram they have been included under Q3.1 only.

(c) One article identified was applicable to Q3.3, Q3.4, Q3.5 and Q3.6, for the purposes of this diagram it has been included under Q3.3 only.

Appendix H – Economic evidence tables

There were no health economic studies found in the review.

Appendix I – Health economic model

No original economic modelling was undertaken.

Appendix J – Excluded studies

Clinical studies

Table 18: Studies excluded from the clinical review

Reference	Reason for exclusion
Aaboe 2011 ¹	Non-comparative study
Anandacoomarasamy 2012 ²	No usable outcomes (reported radiographic parameters only)
Bartels 2014 ⁵	Non-comparative study
Bliddal 2011 ⁴	Commentary only
Brennan 2010 ⁶	Wrong population (studies the effects of weight gain)
Chu 2018 ⁷	Systematic review (inadequate quality assessment, includes study designs not included in the protocol for this review)
Cuzdan Coskun 2017 ⁸	Wrong population (includes healthy participants)
Daugaard 2020 ⁹	Results not stratified by weight loss
de Luis 2012 ¹⁰	Does not report a regression analysis and baseline values for confounders were not comparable at baseline (specifically baseline values for symptoms)
DeClercq 2017 ¹¹	Wrong population (includes people with rheumatoid arthritis)
Edwards 2012 ¹²	Does not account for confounding factors adequate and outcomes not usable (reported medians and interquartile ranges)
Felson 1996 ¹⁴	Systematic review (methodology inadequate for inclusion in this review)
Felson 2004 ¹⁵	Results not stratified by weight loss
Felson 2021 ¹³	Incorrect prognostic variable (not stratified by amount of weight loss)
Fonseca Mora 2020 ¹⁶	Studies different types of surgical weight loss procedures and does not stratify results by amount of weight loss
Gersing 2016 ¹⁹	No usable outcomes (reported biomechanical parameters only)
Gersing 2019 ¹⁷	No usable outcomes (reported biomechanical parameters only)
Gersing 2019 ¹⁸	No usable outcomes (reported radiographic outcomes only)
Gorsky 1996 ²⁰	Wrong study type (economic study using hypothetical cohorts)
Gudbergesen 2013 ²¹	No usable outcomes (reported biomechanical parameters only)
Guimaraes 2018 ²²	No usable outcomes (reported biomechanical parameters only)
Hacken 2019 ²³	Results not stratified by amount of weight loss
Hall 2019 ²⁴	Results not stratified by amount of weight loss
Hamdi 2018 ²⁵	Non-comparative study
Hawker 2014 ²⁶	Results not stratified by amount of weight loss
Inacio 2014 ²⁷	Wrong population (people who had total joint arthroplasty surgery)
Jafarzadeh 2018 ²⁸	No usable outcomes (reported radiographic parameters only)
Jin 2021 ²⁹	No usable outcomes (reported rates of surgery only)
Kallchman 2007 ³⁰	Non-comparative study
Kannus 1988 ³¹	Wrong population/study type of interest (study investigates people after acute ligament injury and investigates whether they develop osteoarthritis)
Kim 2020 ³²	Wrong study type (cross-sectional study)
King 2015 ³³	Wrong population (people without osteoarthritis)

Reference	Reason for exclusion
King 2016 ³⁴	Wrong population (people without osteoarthritis)
Larsen 1980 ³⁵	Wrong comparison (compares people being given surgery to people being told to lose weight before surgery is attempted)
Li 2019 ³⁶	Non-comparative study
Magnusson 2015 ³⁷	Results not stratified by amount of weight loss
Martin 2001 ³⁸	Stratifies by BMI category. However, the amount of weight loss was the same category for both groups. Inadequate data adjustment for confounding factors.
Messier 2007 ³⁹	Commentary only
Messier 2021 ⁴⁰	Wrong prognostic variable (study weight regain rather than weight loss)
Messier 2021 ⁴¹	Duplicate reference (Messier 2021 ⁴⁰)
Moss 2016 ⁴²	Non-comparative study
Munugoda 2020 ⁴³	No usable outcomes (reported radiographic outcomes only)
Murphy 2016 ⁴⁴	Non-comparative study
Nicholls 2012 ⁴⁶	Non-comparative study
Nuesch 2011 ⁴⁷	Non-comparative study
Paans 2013 ⁴⁸	Non-comparative study
Pellegrini 2016 ⁴⁹	Non-comparative study
Pi-Sunyer 1996 ⁵⁰	Systematic review (methodology inadequate for inclusion in this review)
Pogacnik Murillo 2017 ⁵¹	Results not stratified by amount of weight loss
Ravikumar 2020 ⁵²	Results not stratified by amount of weight loss
Reyes 2016 ⁵³	Results not stratified by amount of weight loss
Richette 2011 ⁵⁴	Results not stratified by amount of weight loss
Rishi 2018 ⁵⁶	Results not stratified by amount of weight loss
Rosemann 2008 ⁵⁷	Results not stratified by amount of weight loss
Sarumathy 2016 ⁵⁸	Results not stratified by amount of weight loss
Serebrakian 2015 ⁵⁹	No usable outcomes (reported radiographic parameters only)
Shin 2014 ⁶⁰	Results not stratified by amount of weight loss
Tanamas 2013 ⁶¹	Wrong population (includes healthy participants)
Teichtahl 2015 ⁶²	Wrong population (people without osteoarthritis)
Trofa 2014 ⁶³	Wrong population (people after arthroplasty surgery)
Ustun 2019 ⁶⁴	Results not stratified by amount of weight loss
Veronese 2018 ⁶⁵	Non-comparative study
Vincent 2012 ⁶⁶	Systematic review (methodology inadequate for inclusion in this review)
Visser 2014 ⁶⁷	Results not stratified by amount of weight loss
White-O'Connor 1989 ⁶⁸	No usable outcomes (studies dietary choices between people in different BMI categories)
Wluka 2013 ⁶⁹	Systematic review (methodology inadequate for inclusion in this review)
Yoshimura 2012 ⁷⁰	Non-comparative study
Zeng 2021 ⁷¹	Wrong prognostic variable (whether a person had bariatric surgery or not)

Health Economic studies

Published health economic studies that met the inclusion criteria (relevant population, comparators, economic study design, published 2005 or later and not from non-OECD country or USA) but that were excluded following appraisal of applicability and methodological quality are listed below. See the health economic protocol for more details.

None.